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13. ICA  - Islet cell  cytoplasmic Antibodies. 
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48. DIC  - Disseminated intra vascular coagulation. 
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ROLE OF URICACID & hs-CRP AS RENAL AND      
CARDIOVASCULAR RISK MARKERS IN TYPE 1 DIABETIC 
PATIENTS WITH LOW GFR 
 
ABSTRACT: 
AIMS AND OBJECTIVES : 
 Recent studies  have reported  that  high serum  levels of uric acid  and hs-CRP  
are strongly associated with  impaired renal function  and  cardio vascular disease. 
This study aims to find out the role of uric acid & hs-CRP in  detection of early renal 
function decline  before the onset of proteinuria and  detection of cardiovascular risk 
in type 1 Diabetic patients  . 
 
METHODOLOGY: 
 A total of 130 type 1 Diabetic patients (65 normoalbuminuric  & 
65microalbuminuric) were recruited  in the cross sectional  study. Uric acid & hs-CRP 
were measured by enzymatic colorimetric method & ELISA method respectively. 
Other metabolic parameters  blood pressure, bodymassindex,HbA1c, Fasting plasma 
glucose, Plasma lipid profile, serum creatinine, urine albumin creatinine ratio were 
assessed. Estimated  Glomerular filtration rate was  calculated by CKD-EPI equation. 
 
RESULTS: 
 The respective mean uric acid levels in normoalbuminuria &  
microalbuminuria were 3.92+/-1.59 & 4.99+/-2.48mg/dL(p-0.004) .Mean hs-CRP 
levels in normoalbuminuria was 1.93+/-2.14mg/L and in microalbuminuria  it  was 
4.47+/-3.05mg/L(p<0.001). Urinary albumin creatinine ratio in normoalbuminuria 
was 13.64+/-7.66 and in  Microalbuminuria it  was 127.98+/-81.23(p <0.001).In 
normoalbuminuria mean GFR levels  were 110.40+/-20.30ml/min  and in 
microalbuminurics  it was 100.25+/-27.12ml/min.(p-0.02). eGFR >90ml/min  was 
present in 54.5% of normoalbuminurics & 45.5% of microalbuminurics. eGFR 
<90ml/min was  present in 34.5%   of normoalbuminurics and 65.5 %  of  
microalbuminurics. Lower  GFR was strongly & independently  associated with 
elevated serum uric acid & increased urinary albumin creatinine ratio. hs-CRP was 
positively correlated with uric acid  (p-0.04) and Uric acid was negatively correlated 
with e GFR (p-<0.001). 
 
CONCLUSION: 
 Serum uric acid in high normal range  & elevated hs-CRP levels were 
associated  with  impaired renal function in  patients with  type1 diabetes. Therefore it 
can be used as  markers for detecting  cardiovascular risk & early renal function 
decline in patients with type 1 diabetes in Indian clinical setting , where detection rate 
is lower & complications are higher.  
 
KEY WORDS:  
 Type 1 Diabetes, Serum Uric acid, hs-CRP, GFR. 
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INTRODUCTION 
 
 Diabetes Mellitus represents a heterogenous group of disorders, which is 
characterised by Insulin insensitivity and /or hyposecretion. 
 
 Prevalence of diabetes is increasing globally and it is one of the major 
health problems of the 21st century. 
 
EPIDEMIOLOGY: 
 The Estimated number of People with Diabetes Worldwide was 366 
Million in 2013 and it is expected to rise around 522 Million in 2030(1). 
 
 About 62.4 Million people currently have Diabetes in India (2) and it is 
expected to rise around 101.2 Million by 2030(3). 
 
 The burden of Diabetes is primarily due to its many complications. 
Diabetic Nephropathy & Coronary artery disease are the common Micro 
vascular & Macrovascular complications of Diabetes. 
 
 Diabetic Nephropathy affects 20-30% of both Type1 and Type 2 Diabetic 
patients (4). ESRD develops in 50% of Type1 diabetic individuals compared to 
20% in Type 2 diabetic individuals.(5) Prevalence of coronary artery disease 
among  Diabetic Indians ranges from 9% to 14%.and it increases with age and 
duration of Diabetes.(6) 
 
 Microalbuminuria is considered as the earliest clinically detectable stage 
of Diabetic Nephropathy, at which appropriate interventions can reverse or 
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retard the progression of Diabetic kidney disease (7). It is also considered as the 
marker of cardiovascular morbidity & Mortality in Type 1 Diabetes. 
 
 Recent studies have reported that, Uric acid &hs-CRP are well known 
markers for detecting Renal & Cardiovascular damage at an earlier stage before 
the onset of Microalbuminuria. 
 
 Increased serum concentrations of Uric acid induce endothelial 
dysfunction, glomerular hypertrophy, afferent arteriolar wall thickening, inhibit 
the production of nitric oxide & promote the development of Microalbuminuria. 
Thus this study was conducted with an aim to find the role of uric acid and hs-
CRP in normoalbuminuric and Microalbuminuric Type 1 Diabetic patients with 
low GFR. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature   
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REVIEW OF LITERATURE: 
 
DIABETES MELLITUS: 
 Diabetes Mellitus is a metabolic disorder of multiple etiologies due to 
defect in insulin secretion, action or both. It causes disturbances of 
carbohydrates, fat & protein metabolism (8).Incidence of type 1 Diabetes is 5-
10% worldwide. (9) It causes a long-term damage & impaired function of various 
organs especially Eyes, Heart, Blood Vessels, Nerves and Kidney. 
 
TYPE 1 DIABETES: 
 Type 1 diabetes is characterised by hyper glycaemia due to destruction of 
beta cell of pancreas resulting in absolute deficiency of insulin. It is of three 
types. 
 
Type1a: 
 Polygenic & the most common form. 
 80-90%  of  the cases  fall in this category  
 Autoimmune mediated , characterised by the  presence of Glutamic  acid  
decarboxylase,  Islet cell cytoplasmic antibodies and Insulin  auto 
antibodies  that  causes  beta cell  destruction. 
 Type 1a subtypes   : 
1) LADA (Late onset autoimmune diabetes of adults):  
It occur in >30 years of age, associated with other autoimmune 
conditions(10).  
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2) Monogenic type 1 diabetes: 
 
It corresponds to Type1 diabetes of autoimmune poly glandular syndrome 
type 1A (11) & IPEX SYNDROME. (Immune dysfunction poly 
endocrinopathy, enteropathy, X linked.) (12) 
 
Type1b: 
 Idiopathic. 
 No evidence of autoimmunity. 
 It has all the clinical features of type 1a. 
 
Type 1b subtype: 
 Fulminant diabetes, mostly found in Asians. 
 No autoimmune etiology. 
 Impairment of α & β cells of pancreatic islets. 
 It is  most often found in childhood (Juvenile onset diabetes) 
 
Mixed or Double : ( Type1 + Type2): 
 Type 1a autoimmunity & Type 2 (obesity, insulin resistance, 
dyslipidemia) diabetes characteristics in the same individual. 
 
EPIDEMIOLOGY OF TYPE 1 DIABETES: 
 Incidence of Type 1 Diabetes is 5-10% worldwide. 
 In India, the incidence is 6.4/lakh population. 
 Majority of Type 1 cases are less than 20 years of age with highest   
incidence among children of 0-4 years (13, 14, 15). 
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 In young  populations, boys& girls are equally affected.(17) 
 
PATHOGENESIS OF TYPE1 DIABETES MELLITUS: 
GENETIC FACTORS: 
1) MONOGENIC FORMS: 
 Type1a is rarely caused by mutation defect in single gene. 
  Other autoimmune conditions also accompany this due to disruptions of 
common regulatory pathway. 
 In  IPEX syndrome (Immune dysregulation polyendocrinopathy, 
enteropathy X linked.) ,  the  mutation  in  FOXP3  transcription factor  
leads to dysfunction  of T cell regulation(18,19,20). 
 80% of affected children develop autoimmune diabetes early. 
 
GENETIC STUDIES AMONG TWINS HAVING TYPE 1 DIABETES: 
 About 10% of Type 1 Diabetes has a parent or sibling with the disease. 
 Monozygotic twins have 50%concordance for type 1Diabetes& 
Di zygotic twins have 10% concordance. Even though the concordance 
rate is higher in monozygotic twins, there are divergences in terms of 
time to develop type1 diabetes. i.e.)environmental factors  also  play a  
role  in  diabetic development.(21,22) 
 
2) HLA GENES: 
 HLA complex located in chromosome 6 carries more than 200 genes and 
contributes 50% genetic susceptibility to type1 diabetes. 
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  It  is  located  in cell membrane and present as processed antigen , which  
is  recognised  by  T  cell  receptor. 
  In HLA complex, I-III classes are identified. HLA Class II genes are the 
strongest genetic contributor of   type 1 diabetes. Dominant influence of 
class II alleles has been attributed to HLA-B & HLA-A genes. 
  Two HLA class II haplotypes DR3-DQ2 & DR4-DQ8 carries high risk 
(5%) & early onset disease. 
  Genotype having DR15-DQ6 haplotype is protective, present in 1% of 
children with Diabetes even in the presence of Type 1 Diabetes associated 
antibodies (23). 
 
3) INSULIN GENE: 
 The promoter region of insulin gene on chromosome 11 gene carries a 
genetic susceptibility of 10 %( 24). 
 Susceptibility is proportional to the variable number of Tandem repeat 
polymorphisms in insulin gene promoter region. 
  VNTR Type1 (shorter repeats) homozygous individuals is the highest 
risk category compared to VNTR Type 3(longer repeats), which protects 
against type 1 diabetes. 
 Increased insulin gene expression with class III allele confers greater 
tolerance to insulin precursor molecules (25). 
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Other susceptibility genes: 
More than 40 genes make minor contributions to type 1 Diabetes. Some of them 
are: 
1) PTPN22 (Lymphoid protein Tyrosine phosphatase). 
 New member of Type1 susceptibility gene is PTPN22 which encodes 
lymphoid protein tyrosine phosphatase located on chromosome 1.It is a negative 
regulator of T-cell receptor signalling.  
 
INTERLEUKIN -2 RECEPTOR -α (IL2RA) 
 Alpha chain of IL-2 receptor complex located on chromosome 10, 
expressed on T cells upon activation & on natural regulator T cells at base line. 
Increased level of soluble IL2Rα in other autoimmune conditions has the 
potential to neutralise IL-2 & impairs Tregs functionality. (26, 27) 
 
CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN-4 (CTLA4) 
It is located on chromosome 2q33, expressed only on activated T lymphocytes;   
it is a negative regulator of immune response. Mutation in CTLA-4 leads to 
persistence of lymphocyte activation & failure of immune tolerance (28). 
 
INTERFERON INDUCED HELICASE -1(IFIH1) 
 IFIHL polymorphism links genetic with environmental factors. It 
interferes with proper detection & clearance of viral infection and leads to 
abnormal diabetogenic immune response. (29) 
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IMMUNOLOGICAL FACTORS: 
 Type 1 Diabetes is characterised by the presence of humoral antibody & 
T cell responses to islet cell proteins. (Antigen). 
 
Major Beta cell auto antibodies: 
1) ICA (Islet cell cytoplasmic antibodies): 
 It   is present in 75-85% of Type 1 Diabetes. 
 It reacts  with  a sialoglyco conjugate  antigen  present  in the  cytoplasm  
of  all  endocrine cells  of  pancreatic  Islet. 
 
2) Insulin & Proinsulin Auto antibodies: 
 It  is  present  in  more than 90% of  children  who  develop  type 1 
Diabetes  before  age five and in  less  than  40%  of  individuals  who  
develop  Diabetes  after  age  12. 
 It also develops in persons who use human insulin. 
 
3) GAD (Glutamic acid decarboxylase): 
 It is present in 65 K Da form in human islet. 
 It  have  been found up to 10 years  before  the  onset  of  clinical  type 1 
Diabetes. 
 It is present in 60% of patients with newly diagnosed Diabetes.’ 
 It  is  used  to  identify  patients  with apparent  type2  Diabetes  who  
may  progress  to  type 1  diabetes. 
 
  
9 
 
4) Insulinoma associated antigens (IA-2A and IA-2βA): 
 It is directed against two tyrosine phosphatases. 
 It is detected in more than 50% newly diagnosed type 1 Diabetes. 
 
5) Zinc Transporter (ZnT8): 
 It is present in 60-80% of Type 1 Diabetes. 
 
METABOLIC DYSREGULATION FOUND IN CHILDREN WHO 
LATER DEVELOP TYPE 1 DIABETES: 
  Oresic et al states that “Metabolic dysregulation precedes autoimmunity” (30) 
Increased serum concentration of lysophosphatidyl choline, precedes the 
appearance of each islet auto antibody. Lysophosphatidylcholine is generated by 
hydrolysis of phosphatidylcholine by phospholipase A2. It increases the 
susceptibility of β cells to oxidative damage.  
 
Changes in serum metabolites such as 
 Decrease in succinate 
 Decrease in Phospholipid 
 Decrease in keto leucine 
 Increased  Branched  chain  aminoacids 
 Increased glutamic acid is found in children who later develop type 1 
diabetes. These by products are capable of producing  reactive  
oxygen species  and  causes  β cell  destruction.(31) 
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2) PRECIPITATING CAUSES FOR TYPE 1 DIABETES: 
VIRAL INFECTIONS: 
 Enteroviruses specifically coxsackie viruses B up regulate chemokine 
CXCL10 in pancreatic beta cells (32) .Congenital rubella syndrome is associated 
with HLA-A1-B8 susceptibility haplotype. 
 
 Viruses  may  damage the  beta cell by  direct  invasion  or  by  triggering  
an  autoimmune  response. They  may  also  persist  within  beta  cells  and  
cause  long term  interference  with  metabolic  and   secretory  function. 
 
BACTERIA: 
 Autoimmunity ensues whenever the microbial balance in the intestine is 
disturbed. "Leaky gut phenotype" exists in type 1 diabetes & it enhances the 
exposure of bacterial antigen in the intestine to immune system. 
 
 Mutant forms of SLC11A1 alter the process and leads to diabetogenic 
responses (33). 
 
ENVIRONMENTAL FACTORS: 
1) DIET: 
 Prolonged cow’s milk consumption promotes islet autoimmunity.   
 The bovine  serum albumin (BSA) an  antigen  may  enter  in   an  intact  
form through  the  gut  of  neonates  and  stimulate an  immune  response  
directed  against  β cells.(34) 
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 PTPN22 polymorphisms affect islet autoimmunity only if children are 
exposed to cow’s milk during early infancy (35). 
 
2) WHEAT PROTEINS: 
 Immunity to oral proteins is altered in Type 1 Diabetes. Increased 
peripheral blood T cell reactivity to wheat Gluten was found(36).But  the  cell  
reactivity to  Gluten  is  not  related  to  HLA DQB1*0201,a  risk allele  for  
Type1 Diabetes.  
VITAMIN-D: 
 Interactions between Vitamin D Receptor & HLA alleles are mediated by 
Vitamin D responsive element present in HLA-DRB1-0301 allele. 
 
 Complete deficiency of vitamin D results in type1 Diabetes due to poor 
expression of DRB1-0301 in Thymus. (37) 
 
 
Genetic susceptibility. 
 
Environmental Trigger (Viruses, Toxins) 
 
Immunological Activation (Autoimmunity) 
 
Progressive Beta cell destruction 
 
Type 1 Diabetes 
 
 
Fig-1: Sequence of Events in the Development of Type 1 DM. 
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DIABETIC NEPHROPATHY: 
 Diabetic Nephropathy   is the most common cause of glomerulosclerosis 
&End stage renal disease. It occurs in 20-40% of uncontrolled Type 1 Diabetic 
patients. It is a syndrome characterised by 
 Declining Glomerular filtration rate. 
 Albuminuria   
 Arterial hyper tension. 
 
It increases the cardiovascular risk, affecting 20-40% of Diabetic patients. (38) It 
starts in the first decade of life in Type 1 diabetes. Pure Diabetic 
Glomerulopathy is commonly observed in patients with earlier onset of Diabetes 
& it is evaluated at the stage of Incipient Nephropathy. (39) 
 
 Tubulointerstitial damages are seen at the stage of Overt Nephropathy 
with arterial hypertension in older patients (40). 
 
Natural history of Diabetic Nephropathy: 
 It differs based on the Type of Diabetes & the presence of 
microalbuminuria. If untreated, 80% of Type 1 Diabetes will progress to Overt 
Nephropathy compared to 20-40% in Type 2 Diabetes over a period of 15 years. 
 
 Mauer& colleagues (41) states that, in Type 1 Diabetes with 
microalbuminuria, histological alteration were detected such as 
 Glomerular  hyper filtration 
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 Hyper perfusion 
 Thickness of Glomerular basement membrane  
 Mesangial expansion   and they   progress to Overt Nephropathy. 
 
 It is highly variable & it is influenced by other factors such as Glycemic 
control& Blood pressure. 
 
 
Hyper glycaemia 
 
Increased Glomerular filtration Rate. 
 
Microalbuminuria 
 
Frank Proteinuria 
 
Decreased Glomerular filtration Rate. 
 
Possible development of Nephrotic syndrome. 
 
End stage renal disease. 
 
 
Fig2:  Natural History of Diabetic Nephropathy. 
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RISK FACTORS OF DIABETIC NEPHROPATHY: 
1) Genetic: 
 Cell membrane  cation transport  system  namely  the  red cell (Na-Li 
counter transport ) is genetically  determined  and it  is involved in the renal  
resorption  of  sodium  & regulation of B.P. 
 
 In susceptible individuals, environmental changes induce cell hypertrophy 
& hyperplasia leading to glomerular hypertrophy & mesangial expansion. 
 
 The altered sodium balance leads to glomerular hypertension, increased 
glomerular filtration rate   causing proteinuria. 
 
2) Duration of Diabetes: 
 During first 5 years, Nephropathy is rare. The incidence reaches a peak by 
15th year and rarely develops after 25 years of Diabetes. 
 
3) Hypertension: 
 Presence of Hypertension indicates renal involvement. Incidence of 
hypertension increases with progression of renal disease. 
 
4) Hyper glycaemia: 
 GFR is positively correlated with HbA1c. Progression of Nephropathy is 
arrested with adequate metabolic control. 
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5) Smoking: 
 Smoking causes Vasoconstriction, coagulation abnormalities & platelet 
dysfunction which can accelerate vascular damage. 
 
STAGES OF DIABETIC NEPHROPATHY: 
There are five stages of Diabetic Nephropathy based on 
1) Changes in Glomerular filtration rate. 
2) Albuminuria & proteinuria. 
3) Changes in arterial pressure. 
4) Structural changes. 
 
Stage 1 :( Stage of Hyper function& Hypertrophy) 
1) GFR is>150 ml/min. 
2) Normal Blood pressure. 
3) Urinary albumin excretion may be increased. 
4) Large Kidneys with Glomerular hyper filtration &Hypertrophy 
 
Stage 2 :( silent stage) 
1) GFR is normal or increased. 
2) Normal Blood pressure. 
3) Urinary albumin excretion is normal. 
4) Increased basement membrane thickening & mesangial expansion 
may be present. 
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Stage 3 :( Stage of Incipient Diabetic Nephropathy) 
1) GFR is normal or increased. 
2) Blood pressure increasing by 3mmHg/year. 
3) Persistent microalbuminuria (20-200µg/min.) 
4) Increased basement membrane thickness with mesangial expansion. 
 
Stage 4 :( Stage of overt Diabetic Nephropathy) 
1) Fall in GFR 
2) Hyper tension. 
3) Macroalbuminuria (>200µg/min). 
4) Increasing Glomerular occlusion& severe mesangial expansion. 
 
Stage 4 :( stage of ESRD) 
1) GFR<20ml/min. 
2) Frank hyper tension. 
3) Macroalbuminuria often decreasing, due to Glomerular occlusion. 
4) Uraemia with Glomerular occlusion & mesangial expansion. 
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TABLE: 1: ALBUMIN EXCRETION AND ALBUMIN CREATININE RATIO. 
 
CONDITION 
24hr URINARY 
ALBUMIN 
EXCRETION 
RATE 
URINARY 
ALBUMIN 
EXCRETION 
RATE 
ALBUMIN 
CREATININE  
RATIO 
MACROALBUMINURIA >300mg/day. >200µg/min. >25mg/mmol. 
MICROALBUMINURIA 30-300mg/day. 20-200µg/min. 
2.5-25mg/mmol 
(FOR MEN) 
3.5-25mg/mmol 
(FOR WOMEN) 
NORMOALBUMINURIA <30mg/day <20µg/min. 
<2.5mg/mmol 
(FOR MEN) 
<3.5mg/mmol 
(FOR WOMEN) 
 
 
PATHOGENESIS OF DIABETIC NEPHROPATHY: 
The main pathophysiological mechanisms causing Diabetic Nephropathy are 
1) Hemodynamic pathway. 
2) Metabolic pathway. 
i)  Non enzymatic Glycosylation. 
ii)  Polyol pathway. 
iii)  Protein kinase c pathway. 
iv)  Biochemical abnormalities of Extracellular matrix. 
 
3) Intracellular factors/Growth factors& cytokines. 
HEMODYNAMIC PATHWAY: 
 The early signs of Glomerular hyper filtration & hyperperfusion are due 
to decreased efferent& afferent arteriolar resistance. The factors such as 
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1) Nitric oxide 
2) Vascular endothelial growth factor 
3) Transforming growth factor -β1 
4) Prostanoids 
5) Renin angiotensin system particularly angiotensin II are responsible 
for defective auto regulation. 
 
 These changes causes thickening of Glomerular Basement membrane, 
Mesangial matrix expansion, injury to podocytes & release of cytokines 
&Growth factor (42). 
 
 Blockade of Angiotensin II by the use of Angiotensin & aldosterone 
blockers will preserve kidney function. (43).  
 
2) METABOLIC PATHWAY: 
 Hyperglycaemia is an important factor in the development of Diabetic 
Nephropathy. It causes Mesangial cell expansion & Basement membrane 
thickening. 
 
 Mesangial cell modulated Glomerular filtration via smooth muscle 
activity (44). 
 
 Mesangial cell expansion is mediated by increased Glucose concentration 
in mesangial cells or by increase in Glucose transporters. (GLUT1&GLUT4)(45). 
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 It increases the vascular permeability by upregulation of VEGF 
expression in podocytes. (46) 
 
 Three mechanisms have been postulated to explain the effect of hyper 
glycaemia in tissue damage. 
 
1) Advanced Glycated end products: 
 Glucotoxicity leads to the formation of advanced glycation end products 
by non enzymatic glycosylation of intracellular proteins where Glucose & other 
glycating compounds attach to aminogroup& other molecule such as nucleic 
acid without the aid of enzyme, producing reversible early glycated end products 
(schiff base) and later, irreversible (Amadori products). 
 
 These products are slowly converted in to advanced glycated end 
products. 
 
 It accumulates in tissue (arterial wall& Glomerular basement membrane) 
by cross linking with the collagen causing atherosclerosis & Glomerular 
dysfunction. 
 
 It alters the signal transduction by altering the level of cytokines, 
hormones & free radicals and contributes to renal & microvascular 
complications. (47). 
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2) Protein kinase C pathway: 
 Hyper glycaemia  activates  protein kinase C  by  denovo formation of  
diacylglycerol & oxidative stress(48) leading to secretion of vasodilatory 
prostanoids,TGF-β1 which  contributes to Glomerular hyper filtration & 
mesangial cell expansion.(49) . 
 
3) Polyol pathway: 
 When intracellular Glucose concentration is raised, Glucose metabolism 
takes place via sorbitol pathway by the enzyme aldose reductase. It   is present in 
mesangial cells, distal tubular cell, and glomerular epithelial cell of normal 
kidney. It generates sorbitol in response to high salinity in medullary 
interstitium. Sorbitol causes 
 
a) Defect in inositol signalling. 
b) Depletion of Myo inositol. 
c) Decreased NaK ATPase activity. 
d) Decreased intracellular NADPH leading on to Oxidative injury. 
 
4) BIOCHEMICAL ABNORMALITIES OF EXTRA CELLULAR 
MATRIX: 
 In Diabetic Nephropathy, thickness of Glomerular basement membrane & 
mesangial matrix increases. 
 Synthesis of collagen in Extracellular membrane is also increased. The 
lysyl hydroxylase enzyme involved in hydroxylation of peptide bound 
lysine during collagen biosynthesis is increased.  
21 
 
 In Diabetes, denovo synthesis of GAG content of GBM is decreased 
leading to loss of negative charge which results in fusion of foot process 
& obliteration of slit & diaphragm and ends in albuminuria. 
 Glycosylation of GBM leads to increased cross linking of disulfide 
bridges between collagen via increased oxidation of sulfhydryl groups 
which affects the architecture of GBM due to the presence of reactive 
carbonyl group of Glucose attached to these structures .It results in linear 
deposition of albumin & IgG along the Glomerular & Tubular membrane. 
 Membrane bound receptor  which  selectively  scavenges the removal  of  
cross linked denatured proteins induces the synthesis of  Macrophages 
&Monokines (IL-1,TNFα).These Monokines  initiate  a cascade of stimuli 
resulting in  increased cellular proliferation ,protein synthesis  & Vascular 
permeability leading to albuminuria. 
 
3) GROWTH FACTORS & INFLAMMATORY CYTOKINES: 
a) GROWTH FACTORS:  
1) Transforming Growth factor -β: 
 Endogenous TGF-β under hyperglycaemic conditions is able to enhance 
Glucose transport by over expression of mRNA &protein GLUT-1.i.e) it 
accelerates the Glucose induced abnormalities of mesangial cells. 
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2) Platelet derived growth factor: 
 Hyper glycaemia induces an early stimulation of PDGF which causes an 
increased TGF-β1 expression results in mesangial cell expansion. 
 
3) Connective Tissue Growth Factor: 
 It increases fibronectin, collagen types I & IV, Transient actin 
cytoskeleton disassembly in mesangial cell leading to mesangial cell 
hypertrophy. 
 
4) Growth Hormone & Insulin Like Growth Factors: 
 Normally Growth hormone secreted from pituitary induces the synthesis 
of Insulin like Growth factor through activation of Growth hormone Receptor. 
Growth hormone is involved in the pathogenesis of Glomerulosclerosis 
independent of IGF-1. 
 
 It increases laminin, Type IV collagen, Fibronectin & proteoglycan.  
 
5) Vascular Endothelial Growth Factor: 
 Hyperglycaemia stimulates VEGF that mediates endothelial injury in 
Diabetes. (50) 
 
 It stimulates α3 chain of collagen IV and contributes to thickening of 
GBM. 
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INFLAMMATORY CYTOKINES: 
 Inflammatory cytokines (IL-1, IL-6, IL-18, and TNF) are involved in the 
progression of Diabetic nephropathy. 
 
 IL-1 alters the expression of chemotactic factor, intraglomerular 
hemodynamics, increases the permeability of endothelial cell, and increases 
hyaluron production, which in turn increases Glomerular cellularity. (51). 
 IL-6: Involved in GBM thickening & increases Glomerular permeability. 
 IL-18: Induces the production of other cytokines such as IL-1, IF-γ& TNF. 
 TNF: Causes early hypertrophy & hyper function of Diabetic 
Nephropathy.(52) 
 
OXIDATIVE STRESS: 
 The metabolism of Glucose via harmful alternate pathway such as 
Advanced Glycated end product formation and Protein kinase C activation are 
partly dependent on reactive oxygen species. Concentration of markers of DNA 
damage produced by reactive oxygen species is higher in patients with severe 
Nephropathy. (53) 
 
CORONARY ARTERY DISEASE: 
 Cardiovascular disease  is  about  twice as  frequent  in diabetic  Men  and  
four  times  as  frequent  in  diabetic  women  after  menopause. The risk is 
proportional to increased HbA1c level (54). 7-10% of Type1 Diabetic patients 
develop coronary artery disease. 
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 In Type 1 Diabetic patients Coronary vascular disease events are 
generally not expected to occur during childhood.  But, the atherosclerotic 
process begins during child hood. The relationship of hyperglycaemia with 
microangiopathy &macroangiopathy is more significant in type1 compared to 
type2 Diabetes. (55, 56) 
 
RISK FACTORS: 
1) Poor glycemic control: 
Atherosclerosis is the cause of major cardiovascular events. Cardio vascular risk 
is increased in patients with metabolic syndrome &Type 1 Diabetes (57). 
 
 Hyperglycaemia causes activation of nuclear factor Kappa B (58, 59) which 
results in expression of several adhesion molecules that facilitate monocyte 
adhesion to endothelial cells (58). 
 
 Monocyte is then converted into macrophages taken up by lipids forming 
foam cells & deposit in the arterial wall leading to fatty streak formation. With 
time, it causes smooth cell proliferation & necrotic core formation. Some of 
these lesions become unstable &rupture leading to clinical symptoms of 
coronary vascular disease. 
 
2) Hypertension: 
 Hypertension & Diabetes increases 10-30% of risk of developing 
macrovascular complications. (60).Blood pressure tends to increase 3 years after 
the development of microalbuminuria (61).  
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3)Dyslipidemia: 
 Auto oxidation of Glucose leads to the formation of super oxide anion 
that facilitates LDL oxidation (62). 
 Scavenger receptors present on arterial macrophages taken up these 
modified Lipoproteins. AGE modified albumin inhibit SRB-1 mediated 
efflux of cholesterol to HDL (63) and interfere with reverse cholesterol 
transport.  
 High glucose concentration alters the delivery & removal of lipid from 
macrophages by modification of lipoproteins. It leads to lipid 
accumulation & foam cell formation. 
 
 It worsens the cardiovascular risk due to increased VLDL, Triglycerides 
& modification of Lipoproteins by oxidation, glycosylation and there is a 
reduction in vascular compliance predisposing to early atherosclerosis (64). 
 
 In Type 1 Diabetes, atherogenesis is not caused exclusively by increase in 
lipid levels, Hyper glycaemia is also pivotal in this process. (65) 
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PATHOGENESIS: 
1) OXIDATIVE STRESS: 
 Oxidative stress results from imbalance between production of reactive 
oxygen species & antioxidant defence mechanism. Reactive oxygen species are 
highly reactive & chemically unstable and function as second messengers 
regulating the expression of redox signal sensitive genes. (Nuclear factor kappa-
B)  & in the production of inflammatory mediators (66). 
 
 They are generated from the enzyme that uses oxygen as the electron 
acceptor including NADPH oxidase, Cyp450, lipo-oxygenase &cyclooxygenase. 
 
 The active form of NADPH oxidase reduces the molecular oxygen 
resulting in the formation of superoxide anion. 
 
NADPH+2O2 NAD (p+) +H++2O2-(67) 
 Reactive oxygen species production are involved in apoptosis, 
hypertrophy, extracellular protein modification, protein synthesis &changes in 
gene transcription (68) In addition superoxide overproduction can divert the 
production of Nitric oxide to generate peroxynitrite (69).Which damage the 
cellular structures such as DNA & proteins (70).In Type1 Diabetic with overt 
Nephropathy, Hyperglycaemia causes increase lipid peroxidation without 
increase in compensatory antioxidant enzymes (71). 
Patients without chronic complications & exposure to shorter duration of 
diabetes have less antioxidant capacity suggesting that Oxidative stress occurs 
early in the disease (72). 
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EPIGENETICS: 
 Epigenetic factors by different types of reactions mediate interplay 
between genes & environment resulting in activation or repression of genetic 
transcription. 
 
 The most important reactions are acetylation &methylation .Brownlee et 
al (73) have demonstrated that" Reactive oxygen species resulting from 
hyperglycaemia, induce mono methylation of Lysine from histone 3 & increase 
the expression of Nuclear factor Kappa-B." 
 
  It increases the transcription of VCAM-1, Monocyte chemo attractant 
protein-1, IL-6&, ICAM-1. 
 
INFLAMMATION: 
 Increase in inflammatory cytokines  such as TNF-α,IL-1,IL-6, Monocyte 
chemo attractant protein, Platelet activating inhibitor, C-reactive protein, 
Visfatin & adiponectin  cause  plaque  instability(74),endothelial injury & 
abnormalities in coagulation ,resulting  in  increased  risk  of  coronary events.(74) 
 
Hypercoagulability: 
 Diabetes causes glycation & oxidation of clotting factors, and increases 
the thrombotic risk. It increases the plasma levels of procoagulant factors (75) and 
decreases the fibrinolytic capacity resulting in hypercoagulability. 
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HYPOGLYCEMIA: 
 In Hypoglycaemia, there is an increase in myocardial contractility, stroke 
volume & cardiac output. In healthy people, arteries have been reported to 
become more elastic with decrease in wall stiffness (76). 
 
 In long term type 1 Diabetes with hypoglycaemia, increased arterial 
stiffness, with fewer falls in CAP (76, 77) increases the workload of the heart. It 
causes abnormal electrical activity in the heart and provokes sudden death. (77) 
 
HYPERGLYCEMIA: 
Intense Glycemic control decreases the cardiovascular complications. It is 
evident from the results of Diabetes complications &control trial 
(DCCT)/Epidemiology of Diabetes interventions &complications trial(EDIC) (78). 
 
 It is because of "Metabolic memory". i.e. Effect of early glycaemic 
exposure is remembered later in target organs resulting in protective or 
deleterious effects. (79) 
 
ENDOTHELIAL DYSFUNCTION: 
 Healthy endothelium is anti atherogenic. It inhibits platelet aggregation, 
smooth muscle cell proliferation & leucocyte adhesion. It synthesizes & releases 
nitric oxide, PGI2 (vasodilatory substance) &Vasoconstrictor substances 
(endothelin-1, ThromboxaneA2&PGH2).It maintains the balance between 
vasodilatory & vasoconstrictory substances to preserve sufficient vascular 
diameter. 
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 Endothelial dysfunction results in reduction of relaxing factors& increase 
in contracting factors. It increases vascular endothelial permeability, leukocyte 
adhesion and impairment in endothelial signal transduction. 
 
 It is an important determinant of inflammatory activity & it can be 
considered as an early marker for coronary vascular disease (80) regardless of the 
presence or absence of complications. 
 Apart from hyperglycaemia, other factors such as genetic &environmental 
factors are also play a role in endothelial dysfunction (81, 82). 
 
CARDIAC AUTONOMIC NEUROPATHY: 
 Cardiac autonomic neuropathy is a common complication of Type 1 
Diabetes. Its prevalence is around 20% and it increases with age & duration of 
Diabetes. It is an important predictor of cardiovascular mortality & morbidity in 
Type 1Diabetes (83). 
 Dysfunction of the autonomic nervous system mediates the development 
of arterial stiffness, Left ventricular hypertrophy & Ventricular diastolic 
dysfunction. 
 
 This type of cardiac sympathetic dysinnervation was identified in long 
term than in newly diagnosed Type 1 Diabetes.(84, 85). 
 Neuronal abnormalities progression correlates with the duration of 
Diabetes(86).Various immunological factors against sympathetic ganglia are also 
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associated with sympathetic dysfunction.(87,88)Auto antibodies against 
sympathetic ganglia are present in 20-35% of Type 1Diabetes(89,90). 
 
URICACID: 
 Uric acid (2, 6, and 8- Tri hydroxy purine) is a heterocyclic organic 
compound. Its molecular weight is 168 Daltons. It is a weak organic acid with a 
P Ka of 5.75. At physiological pH, it exists principally as urate which is more 
soluble than uric acid (91) .At a urine pH  below 5.75, uric acid is the predominant 
form.  
 The daily synthesis rate of uric acid is 400 mg approximately and from 
dietary source is 300 mg. 
  In purine free diet, the total body pool of exchangeable urate is 1200mg in 
men and it is about 600mg in women. It is the end product of purine metabolism. 
 
SYNTHESIS OF URICACID: 
 Catabolism  of  purine  nucleotides begins with removal of ribose linked 
phosphate catalysed by purine 5'-Nucleotidase.Removal of Ribose moiety of 
inosine &guanosine by purine nucleoside phosphorylase forms Hypoxanthine& 
Guanine, both are converted into xanthine. Xanthine is converted to uric acid by 
the action of xanthine oxidase. Renal handling of uric acid is complex and it 
involves  
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 1)Glomerular filtration  
 2)Tubular re absorption of 98-100% of filtered uric acid is by the 
proximal convoluted tubule. 
 3)Secretion of uric acid in to  distal portion of proximal convoluted tubule 
 4)Further reabsorption in the distal tubule. 
 6-12% of filtered uric acid is excreted. Uric acid is degraded in most 
mammals by hepatic enzyme uricase to allantoin& it is freely excreted in the 
urine. Distinct mutational silencing occurs early &makes the uricase gene non-
functional in humans &apes(92)  and that’s why  humans & apes have increased  
uric acid levels than most mammals 
 Uric acid is higher in men & post menopausal women & lower in 
Females because estrogens are uricosuric. Uric acid levels are altered due to 
various factors that increase the production or decrease its excretion. 
Normal Reference range: 
 Male  3to7 mg/dl,   
 Female 2.5-6.5 mg/dl and  
 Daily excretion is about 250-700 mg/dl. 
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CAUSES OF HYPERURICEMIA: 
 Plasma concentration of uric acid is >7.0mg/dl in men and >6.0mg/dl in 
Women. 
 
INCREASED FORMATION: 
PRIMARY: 
Idiopathic 
Inherited metabolic disorder 
SECONDARY: 
Excess Dietary protein intake 
Increased nucleic acid turnover. (Leukaemia, Chemotherapy, 
Radiotherapy, Trauma) 
Psoriasis 
Alcohol 
Tissue Hypoxia 
Preeclampsia 
 
DECREASED EXCRETION: 
PRIMARY :( Idiopathic) 
 
SECONDARY: 
Acute or chronic kidney disease 
Increased renal absorption, reduced secretion 
Lead poisoning 
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Organic acids(Lactate, acetoacetate) 
Preeclampsia 
Thiazide diuretics, Salicylates (low doses). 
 
GOUT: 
 When Monosodium urate   precipitates from supersaturated body fluids, 
the deposits of urate are responsible for the clinical signs & symptoms. 
 Gouty arthritis may be associated with urate crystals in joint fluid and 
deposit of crystals (Tophi) in tissue surrounding the joint.  
 Urate crystals deposited in renal parenchyma results in Gouty 
Nephropathy. 
 
CAUSES OF HYPOURICEMIA: 
Plasma urate concentration is<2mg/dl. 
1) Severe hepatocellular damage with reduced purine synthesis or xanthine 
oxidase activity. 
2) Defective renal tubular reabsorption of uric acid. It may be 
congenital(ex:Fanconi syndrome) or acquired( ex: Injection of 
radioopaque contrast media/chronic exposure to toxic agents  or  over 
treatment  with  allopurinol/ uricosuric drugs ) will  produce  
hypouricemia. 
3) Molybdenum cofactor deficiency. 
4) Purine nucleoside phosphorylase deficiency. 
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HYPERURICEMIA IN CARBOHYDRATE METABOLISM 
 Glucose 6 Phosphatase enzyme catalyses the release of Glucose. 
Deficiency of Glucose 6phosphatase in Von Gierke disease causes 
increased Glucose 6 Phosphate which stimulates pentose phosphate 
pathway and synthesis excess purine& ultimately uric acid. 
 Organic acidemias- Lactic acidosis, Diabetic keto acidosis (Interferes 
with tubular secretion of urate.) 
GENETICS OF URATE TRANSPORTER: 
 Uric acid homeostasis depends on the balance between production, 
reabsorption, secretion & excretion. 30% of uric acid excretion is by the intestine 
& the remaining 70% is by the kidney. Some of the transporters are 
 
1) Organic anion transporter (SLC22Afamily) 
 URAT-1- is the urate/anion exchanger. It is a 12 trans membrane domain 
containing protein, transports urate in exchange for Cl- or organic anions. It is 
found in apical membrane of proximal tubular epithelial cells.  
 
OAT-4&OAT10: 
 OAT4 (SLC22A11 gene) is a multi specific anion transporter present in 
proximal tubular epithelial cell, activated by intracellular dicarboxylates and it is 
involved in luminal urate reabsorption. (93, 94, 95) 
 OAT10 (SLC22A13) is a urate transporter expressed in brush border of 
proximal tubule &collecting ducts (96) 
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OAT1&OAT3: 
 OAT1(SLC22A6)&OAT3(SLC22A8)   function as urate/ dicarboxylate 
exchanger found on baso lateral side(97,98,99,100).OAT3 is found  in  all segments, 
from proximal convoluted tubule to collecting duct. Through organic anion 
transporter, uric acid enters into smooth muscle cell and activates mitogen 
activated protein kinases, cyclooxygenase-2, causes upregulation of PDGF, 
thromboxane formation and increases the cell proliferation. 
 
OTHER TRANSPORTERS IDENTIFIED BY GENETIC ASSOCIATION 
STUDIES: 
 
GLUCOSE TRANSPORTER FAMILY MEMBER SLC2A9: 
 GLUT9 (SLC2A9) has a sequence similar to GLUT family of Glucose 
transporter. (GLUTII isoform)(101).It exists as two alternatively spliced variants 
(GLUT9A, GLUT9B) and encodes different amino terminal tails. (102) GLUT9A 
has wide tissue distribution.GLUT9B is present in Liver& kidney. This kind of 
urate transport is inhibited by uricosuric drugs & Glucose transporter inhibitor. 
 
MONOGENIC MUTATIONS IN SLC2A9; 
 Hypouricemia is linked with mutation. Recent genetic studies show that 
single mutation of a highly conserved cysteine in transmembrane 5 of GLUT9 
causes both liver urate uptake & renal reabsorption defects. (102) 
 R
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decreases the NO availability & also decreases the VEGF stimulated NO 
production. (109) 
6) During adipo gene differentiation of 3T3-L1 cells, addition of uric acid 
increases the reactive oxygen species production by NADPH oxidase and 
plays a role in inflammation. (110) 
 
BIOLOGICAL ROLE OF URIC ACID: 
CARDIOVASCULAR DISEASE: 
 Uric acid plays a role in endothelial function & vascular remodelling 
(111). 
 The enzyme xanthine oxidoreductase has 2 forms. It exists as xanthine 
dehydrogenase in normal physiological conditions that has greater 
affinity towards NAD+ than o2. 
 In ischemic conditions, xanthine dehydrogenase is converted in to 
xanthine oxidase. Here it uses o2 instead of NAD+ as an electron 
acceptor resulting in the formation of uric acid, hydrogen peroxide, 
&superoxide anion. The inflammation & arterial wall damage are 
related to the free radicals produced during the reactions or by uric 
acid itself.(112) 
 It acts as a pro oxidant, increases the reactive oxygen species, 
prevents the reverse cholesterol transport and increases the 
cardiovascular risk. It increases the production of  Monocyte chemo 
attractant protein-1 via, MAP kinase&cyclooxygenase-2  results in 
increased production of c- Reactive protein & cell proliferation(113) 
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RENAL DISEASES: 
 Uric acid induces endothelial dysfunction & local inflammation in 
kidney.  
 It induces phenotypic transition of renal tubules from epithelial to 
mesenchymal (EMT).It increases α smooth muscle actin expression & 
decreases the expression of E-cadherin & Zonaoccludens protein. 
Hypoxia, increased glucose concentration and inflammatory cytokines 
activate the transcription factor which down regulates the expression 
of epithelial cell markers  in tubular epithelial cell and induce 
phenotypic transformation.(114) 
 It is one of the earliest changes which lead to renal fibrosis. Thus uric 
acid induced epithelial mesenchymal transition of renal tubular cell 
explains the association of hyper uricemia & the progression of renal 
disease. 
HYPERTENSION: 
 Hypertension due to hyper uricemia is because of increased renin & 
decreased neuronal NOS-1 in juxta glomerular apparatus (115). 
 It increases the salt sensitivity. The mechanism behind is, 
preglomerular vascular disease produces renal ischemia and generates 
local oxidants by infiltration of Leucocytes and altering the balance of 
vasoregulatory factors resulting in vasoconstriction. This decreases the 
sodium excretion and increases the B.P. 
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 It causes thickening and hypercellularity of glomerulus  with vascular 
remodelling  resulting in increased  medial thickness and decreased  
luminal diameter(116).It damages small renal vessels and leads to 
irreversible salt sensitive Hypertension 
 
INFLAMMATION:  
 DiGovine et all reports that" urate crystals stimulate the production of 
TNF-α from synovial cells& human blood monocytes". 
 MSU induced inflammation are Toll like receptors dependent. This 
Toll like receptors work in synergy with cytosolic receptor families 
NLRS (NOD-Nucleotide binding & oligomerization domain like 
receptors.), and CLR(C type Lectin receptors).MSU activates 
NALP3, a type of NLR leading to the production of protein complex 
called inflammosome. 
 It is involved in the secretion of IL-1β, IL-18, by the activation of 
caspases and induce inflammation.  
 The generation of reactive oxygen species is essential for NALP3 
inflammosome activation. 
 Studies by Liu -Bryan et al demonstrated that, "MSU stimulates the 
dendritic cells and promotes the release of cytokines associated with 
TH17 polarization ". 
 Presence of NF-KB signalling suggests the modulation of adaptive 
immunity in addition to early innate responses.(117) 
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URICACID AND PARKINSONISM: 
 The antioxidant role of uric acid serves as a therapeutic benefit in 
Parkinson’s disease. because oxidative stress plays a role in degeneration of 
dopaminergic neurons in the substantia nigra .So, lowering the level of uric acid 
is associated with Parkinsonism. 
 
PRE ECLAMPTIC TOXEMIA: 
 Increased plasma uric acid concentration is caused by utero placental 
breakdown and decreased kidney perfusion. It correlates with the severity of 
preeclampsia. 
 
 Redman et al states that "concentration in excess of 6mg/dl at 32 weeks of 
gestation is associated with a high perinatal mortality rate". 
 
hs-CRP: 
 hs-CRP was first described by Tillet & France in 1930 in the sera of 
acutely ill patients. This substance was identified as a protein  and has the ability 
to bind the  cell wall polysaccharide of  most bacteria, fungi, parasites & poly 
cations  (histones)  and  it  was  named  as C-Reactive protein. 
 
 It is an acute phase reactant and it is monitored routinely to detect 
infection and autoimmune diseases. 
 
 Numerous epidemiological data show that increased concentration of hs-
CRP predicts future coronary events, peripheral arterial disease and 
cerebrovascular disease (118-120) Traditional assays have the detection limit of 3-8 
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mg/l. To predict cardiovascular risk hs-CRP assays with detection limit of 
<0.3mg/l was developed. 
 
BIOCHEMISTRY OF hs-CRP: 
 C-Reactive protein consists of five identical, non glycosylated 
polypeptide subunits, none covalently linked to form a disk shaped cyclic 
polymer with a molecular weight of 115 k Da. It is synthesized in the Liver, and 
binds to polysaccharide of other organisms. Its production is controlled by IL-6. 
 
QUALITY OF hs-CRP as a Biomarker: 
 Recent epidemiological evidence show that, half of the incidence of 
Myocardial infarction occurs among individuals without hyperlipidemia. Based 
on hemostatic & fibrinolytic function, wide variety of non-lipid biochemical 
markers were developed .ex: VWF, D dimer, Homocysteine, hs-CRP, Tissue 
plasminogen activator antigen. But most of the above markers, except hs-CRP 
cannot satisfy the criteria to be accepted as a biomarker for predicting the   
cardiovascular risk in primary prevention setting (121). 
 
TABLE 2:RECOMMENDATIONS BY CENTRE FOR DISEASE 
CONTROL&PREVENTION (CDC) ANDAMERICAN HEART ASSOCIATION 
(AHA) FOR CLINICAL MEASUREMENT OF hs-CRP: 
1) hs-CRP can be measured both in Fasting & Non fasting state. 
2) When the Test values are >10 mg/l, the result should be discarded and test has to be 
repeated after two weeks. 
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3) For a reliable estimate, an average of two assays performed two weeks apart should 
be considered. 
4) When hs-CRP levels are >10mg/l on two consecutive tests, search for other 
infections and inflammation has to be performed. 
 
TABLE: 3 
Categorization of patients using standard hs-CRP assays to different risk strata: 
Concentration of hs-CRP (mg/l) Risk stratification 
<1.0 mg/l Low Risk 
1.0-3.0mg/l Average risk 
>3.0mg/l High risk. 
 
There are three groups of inflammatory markers. 
1) Cytokines &chemokines. 
2) Soluble adhesion molecule 
3) Acute phase reactants. (122) 
 C-reactive protein is an acute phase reactant, increases in response to 
inflammation & tissue damage (123). Level of CRP increases from 6 hrs and 
reaches a peak with in 48 hrs and have a half life of 19 hrs. The magnitude of 
underlying pathology is detected from its concentration. 
 
STABILITY OF hs-CRP: 
 Based on large number of trials ,it was observed that the concentration  of 
hs-CRP  remained  stable  and it  can be  used as the marker  of future  cardio 
vascular  disease in  community  based  screening.(124) 
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FACTORS THAT INCREASE THE CONCENTRATION OF hs-CRP: 
1) Obesity 
2) Smoking 
3) Metabolic syndrome 
4) Dys lipidemia 
5) Hormones 
6) Hypertension. 
 
FACTORS DECREASING THE CONCENTRATION OF hs-CRP: 
1) Weight loss 
2) Medications:-Statins, Fibrates, Niacin, Aspirin, NSAIDs, Moderate 
alcohol consumption. 
 
SEASONAL VARIATION: 
 Concentration of hs-CRP decreases in summer (lowest found in June), 
and increases in Winter. (November-December). (125, 126) 
 
DIURNAL VARIATION; 
 There is no diurnal variation .It can be measured during any period of 
time .But IL-6, a cytokine, that synthesizes CRP has diurnal variation. 
 
AGE & GENDER INFLUENCE: 
 hs-CRP increases with age & in Women. NHANES111 (Third National 
health and Nutritional evaluation survey) shows the relationship of hs-CRP and 
age. They derived the equation to estimate the hs-CRP based on age. 
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hs-CRP concentration: 
Males  :Age/50 
Females : Age/50+0.6. 
 
RACIAL DIFFERENCE: 
 Based on a systematic review of population studies, south asians, & 
Hispanics have increased hs-CRP concentrations. Average concentration of hs-
CRP in healthy individuals is 2.19mg/L and it is more in people with metabolic 
syndrome. 
 
VARIABILITY AMONG INDIVIDUALS: 
 In individuals with 1) CRP genetic polymorphisms-Elevations of CRP 
concentration without Coronary heart disease risk. 
 
2) Influence of genetic loci mediating CRP response. 
3) Life style factors. 
4) Ethnic factors. 
5) sex. 
 
 There  is  significant  base line variation due  to Diabetes ,Hypertension, 
Dietary patterns, Physical exercise, smoking, Periodontal disease ,Oral 
contraceptive pills  & Environmental pollution. 
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MECHANISM OF ACTION: 
 IL-6 is released from the activated Leukocytes in response to trauma or 
infection. CRP released from IL-6, binds directly with oxidised LDL and is 
present within Lipid laden   Plaques (127).  
 
 CRP catalyses the   early step in atherosclerosis. It causes Monocyte 
adhesion &trans migration in to the vessel wall. It causes polarisation of 
Macrophages, which is a pro inflammatory trigger in plaque deposition in 
atherosclerotic lesions and in adipose tissue. 
 
 In addition, it inhibits endothelial Nitric oxide synthases, and impaired 
Vasoreactivity (128,129).  
 
hs-CRP AND GLOBAL CARDIOVASCULAR RISK TOOLS: 
Based on three scores, 
 Framingham CHD risk score (FRS) 
 Reynolds Risk score (RSS)  
 Systematic coronary risk evaluation. (SCORE)  
 
 Individual cardiovascular risk is assessed for ten years based on 
traditional risk factors. i.e.) Age, Gender, Diabetes, Smoking, Dyslipidemia& 
Hypertension and categorise the patients in to low, intermediate, and high risk. 
CRP is a potential risk factor; it decreases the NO synthesis, promotes 
chemotaxis, & increases the expression of tissue Factor which acts as a 
procoagulant resulting in DIC.  Production of Plasminogen activating inhibitor   
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the risk of future coronary events compared to Metabolic syndrome &hs-CRP <3 
mg/l". (132) 
 
hs-CRP and RENAL DISEASE: 
 hs-CRP predicts the progression and cardiovascular mortality in renal 
disease patients.   
 In Glomerular hyper filtration, the presence of increased inflammatory 
markers signals the worsening of renal function.  
  It also induces Nuclear factor Kappa-B leading to release of vasoactive 
and inflammatory substances in interstitium. The release of cytokine & 
thereby growth factor causes fibroblast proliferation, renal scarring and 
decreases renal function. It indicates, significant inflammatory response 
in early renal dysfunction contributing to progressive deterioration of 
renal function. 
 
hs-CRP AND HYPERTENSION: 
 Increased CRP correlates with endothelial dysfunction.  It activates 
Renin angiotensin system, increases angiotensin II, and up regulates 
angiotensin I receptor activity. 
 
hs-CRP AND TYPE I DIABETES MELLITUS: 
 In hyperglycaemia, the concentration of Advanced Glycated end products 
increases. It activates Macrophages, increases the oxidative stress, up regulates 
the synthesis of IL-6, IL-1& TNF-α resulting in the production of CRP. 
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MEASUREMENT OF GFR: 
 National Kidney Foundation  recommends   Glomerular Filtration  rate  
estimation is necessary for  diagnosis, screening, classification  and monitoring 
of  Chronic Kidney disease(133,134).Without GFR   measurements ,CKD may  
remain silent  and the patient  will land up in End stage Renal disease. 
 
GLOMERULAR FILTRATION RATE: 
 “GFR is a measure of the rate at which water and dissolved substances 
(low molecular weight, ultra filterable compounds) are filtered out of the blood 
per unit time." It provides a measure of filtering capacity of the kidneys. 
 
Urine Concentration * Urine Volume 
  GFR =   
    Plasma Concentration 
 
 
 Normal GFR adjusted for Body surface area=100-130 ml/min/1.73m2 in 
Men &Women. 
 
 In children, GFR measured by Inulin clearance =110ml/min/1.73m2until 
2yrs of age in both sexes. At >40 yrs of age, GFR decreases by about 0.4-1.2 
ml/min/yr. In Indians, accurate  estimation  of  CKD  prevalence  is  limited  due  
to  lack  of  GFR  estimated  equation   validated   for  the  Indian  
population.(135).Indians have   lower  normal  range  of  GFR  than  Western  
population.(136) 
 
 Mean GFR for Indians =95.5+/-11.6ml/min. (137). 
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USES OF ESTIMATION OF GLOMERULAR FILTRATION RATE: 
1) It is an index of functioning renal mass. 
2) Monitoring changes in GFR can delineate progression of Kidney disease. 
3) It is a strong predictor of the time of onset of Kidney failure as well as the 
risk of complications of   CKD. 
4) It allows proper dosing of drugs excreted by Glomerular filtration to 
avoid potential drug toxicity. 
 
PROCEDURES FOR DETERMINING GFR: 
IDEAL FILTRATION MARKER: 
1) Ideal filtration marker is one, which is not protein bound. 
2) Physiologically inert. 
3) Freely filtered by the Glomerulus. 
4) There is no Tubular secretion. 
5) It is not metabolised by the kidneys. 
 
EXOGENOUS SUBSTANCE: 
 Insulin  is  one of the exogenous  substances ,that fulfils  the  above  
criteria and  it  remains  the  Gold  standard   for estimation of  GFR.. Other 
substances used are cr51-EDTA, 99m TC-DTPA and I125-Iothalmate (Require 
estimates of body size.). They are expensive, labour intensive, time consuming, 
and carry some risk to the patient. So these substances are not routinely used in 
screening procedure for the detection of CKD. 
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ENDOGENOUS SUBSTANCE: 
 Creatinine is a naturally occurring endogenous substance and it was  
considered  as the renal marker of  choice  earlier, because  it  is  freely  filtered  
at  the  glomerulus with  minor  absorption  and  secretion  by  the  Renal  
tubules. 
 
TABLE: 4 LIMITATIONS OF CREATININE AS A MARKER FOR GFR: 
 
LIMITATIONS COMMENTS 
Non-Renal Factors 
 Gender 
 Ethnicity 
 Diet, muscle mass. 
 Drugs  which  affect  tubular  secretion of 
Creatinine 
UTILITY 
 Poor sensitivity for CKD "Creatinine blind 
range."(Serum Creatinine remains in the normal 
range until 50% of renal function is lost.) 
Insensitive to loss of  GFR in stage2 &stage 3 of 
CKD 
Analytical Problems 
 Non-specific bias frequently reported with the 
commonly used Jaffe assay(alkaline picrate) 
 
 Use of enzymatic assays for creatinine can 
significantly improve test performance by 
eliminating many source of analytical error. 
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SERUM CREATININE: 
We use serum creatinine for the measurement of GFR because,   
1) Creatinine is one of the filtration markers, whose clearance approximates 
the GFR. 
2) Creatinine excretion is constant among individuals and over time. 
3) Measurement of serum Creatinine is accurate & reproducible across 
clinical laboratories. 
But, these assumptions are not true. Numerous errors occur in the estimation of 
GFR   by using serum Creatinine concentration alone. 
 
CREATININE CLEARANCE: 
 
 
 
 
 Creatinine is a breakdown product of creatine phosphate. Since it is 
actively secreted by peritubular capillaries it overestimates GFR by 10-20 %( 138). 
It varies with muscle mass. It  is  higher  in  younger  than  older people, Black  
than  White, Men  than  women. It also  requires  24 hrs  urine  Creatinine  
excretion  rate; Hence we  use  Cockcroft Gault Formula      
 
COCKCROFT-GAULT FORMULA :( eCcr) 
 A  commonly   used  marker  for  estimating    Creatinine  clearance .It 
estimates  GFR  in ml/min(139).It  requires  Weight, Height, Age and Plasma  
C cr  =  U * V            U = Urine Creatinine Concentration 
     P               V= Volume of Urine 
             P = Plasma Creatinine  Concentration 
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creatinine. It is used for guiding administration of many drugs. It does not 
require 24 hrs urine collection. 
 
It provides useful information for  
1) Estimates  of  GFR  in  individuals with  specific  dietary  
intake.(Vegetarian diet, Creatine supplements) or  muscle  mass 
(amputation, Malnutrition, muscle wasting). 
2) Assessment of diet & Nutritional status. 
3) Need to start dialysis. 
 
LIMITATIONS: 
1) The trial study based on this formula was done only in hospitalised CKD 
patients and only 9 females had participated in the cohort study.  
 
2) It requires height & Weight .It is a cumbersome procedure So, it is not 
used in Lab. 
 
     eCCr    =   (140-age)*Mass (Kg)*0.85(if female) 
  --------------------------------------------- 
              72*serum Creatinine (mg/dl) 
 
MDRD (Modification of diet in renal disease): 
  It  is  based  on Multicentre  trial  to  evaluate  the  role  of  B.P  control 
& dietary  protein  restriction  on  Renal  disease  progression  in  patients  with 
CKD & prediction  of  GFR  from  plasma  Creatinine.(140) . 
 
 MDRD eGFR = 186* (plasma Creatinine (µmol/l) * 0.0011312.)-1.154 .*             
age (years)-0.203 .* 0.742 if female * 1.212 if black. 
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 MDRD (IDMS aligned) =175*(plasma Creatinine (µmol/l)*0.0011312)-
1.154*age (years)-0.203*0.742 if female*1.212 if black. 
 
ADVANTAGES: 
1) GFR is measured directly by urinary clearance of I125iothalamate. 
2) A large sample population of >500 individuals with a wide range of 
kidney disease were studied 
3) It provides eGFR standardised to Body surface area. 
4) Lack of requirement of body weight/height. 
5) Validated in Diabetic kidney disease &renal transplant patient. 
 
DISADVANTAGES: 
1) The formula is derived based on a group of CKD patients. Hence its use 
in healthy population is unclear. 
2) It is not  validated in  children <18 yrs of  age, pregnant Women, >70 yrs  
of age,& in  extremes  of  body  weight. 
3) Limited data  on  the  use  of  eGFR  in other  ethnic  groups. 
4) Calibration  & measurement  imprecision  for  plasma  Creatinine, 
produce  uncertainty  in  e GFR  particularly when the  plasma  Creatinine  
values  are  low, i.e.  Corresponding to higher renal function. (141) 
5) It tends to under estimate renal function in those with an e GFR 
>90ml/min/1.73m2. 
 
Because of these limitations, we use CKD-EPI formula. 
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CKD-EPI (CKD-epidemiology collaboration group): 
ADVANTAGES: 
1) It  met  the  accuracy  of  MDRD  equation  at  GFR  <60 ml/min/1.73m2. 
2) It has greater accuracy   at higher GFR i.e. GFR >60ml/min./1.73m2. It 
decreases the over   diagnosis of CKD with MDRD equation. (142) 
3) It includes Gender, Age, Race & serum Creatinine. 
4) It has different  equations   for  Black, Male, Female, White or  other  
Race  with  different  serum  creatinine   concentrations. 
5) High  accuracy  have  important  applications  in  public  health  as well 
as  in  clinical  practice. 
6) Based   on CKD-EPI, prevalence  of   CKD  is  lower,  when  compared  
to  MDRD, cardiovascular  risk  also  decreases and  the  resources  can  
be  more  appropriately  targeted  for  those  who  are  having  CKD. 
 
CKD-EPI (IDMS CALIBRATED) 
 eGFR=141*min (Serum Cr/K,1)α *Max (Serum Cr/K,1)-1.029 *0.993age 
*(1.018  if  female)*1.159  if  Black. 
 
 K-0.7 for female, &0.9 for Male. 
 
 α is -0.329 for  female&-0.411  for  Male, Min  indicates  minimum  of 
serum  Cr/K or 1,Max-Maximum  of  serum Cr/K or 1. 
 
WHITE OR OTHER RACE (Female) 
 If serum Cr<=0.7 
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 eGFR=144*(serum Cr/0.7)-0.329x0.993Age. 
 If serum Cr>0.7, 
 e GFR=144*(serum Cr/0.7)-1.209x0.993Age. 
 
WHITE OR OTHER RACE (MALE) 
 If serum Cr<=0.9, 
 e GFR=141*(serum Cr/0.9)-0.411xo.993Age 
 If serum Cr>o.9, 
 eGFR=141*(serum Cr/0.9)-1.209x0.993Age. 
MAYO QUADRATIC FORMULA: 
 It  was  developed by Rule et al, It is  mainly  used  to  estimate  GFR  in  
preserved  kidney function. 
 
 eGFR=exp (1.911+5.249/serumCr-2.114)/serum Cr2 -0.00686*age-(0.205 
if female) 
 
 If serum Cr<0.8 mg/dl, use 0.8mg/dl for serum creatinine. 
 
SCHWARTZ FORMULA; 
 It requires serum Creatinine (mg/dl) & height in cm. 
e GFR=K*ht     K-constant depends on muscle mass and varies with child age.              
         serum Cr  
 
 In 1st year of life for preterm babies, k=0.33 & for full term infants 
k=0.45. 
For infants & children of age (1-12 years) K=0.55. 
58 
 
CYSTATIN C: 
 Problems  in  the  estimation of creatinine (varying  muscle mass, protein 
ingestion), led  to the  evaluation  of other  agents  for  estimation  of  GFR. one  
of this  is  cystatin C, an ubiquitous  protein, inhibitor  of  serine  protease, 
secreted  by  most  cells  in  the  body.(143)It  is  freely  filtered  at  the  
glomerulus. It is reabsorbed and  catabolised  by  tubular  epithelial  cells with  
only  small  amount being  excreted  in  the  urine. It is measured in the blood 
stream. 
 
 Equations are developed linking estimated GFR to serum cystatin C   
levels. 
 
Disadvantages: 
1) Lack of international standardised calibrator limits its use. 
2) Expensive.(Will not  justify  its use  until  sufficient  evidence  suggesting   
improved  clinical  decision  making &  better  outcomes.) 
 
Table:5Cystatin C based GFR equation for adults (.144) 
Grubb et al e GFR=84.69*cystatinC-1.680(*0.948 if  female) 
Le Bricon et al e GFR=78/cystatin C (mg/l)+4 
Hoek et al eGFR=80.35/cystatin C (mg/l)-4.32. 
Larsson et al eGFR=77.239*cystatin C(mg/l)-1.2623 
MacIsaac et al eGFR=86.7/cystatin C(mg/l)-4.2 
Rule et al eGFR=76.6*Cystatin C (mg/l). 
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 Clinician   needs  to be  known  about   the  limitations  of  various  
equations  and  to interpret  the  results. Thus  by  reviewing  the  literatures, the  
role  of  Uric acid  and  hs-CRP  in   Type 1 Diabetes with low GFR was  
understood .Hence  this  study  was  carried  out. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims & Objectives   
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AIMS & OBJECTIVES 
 
 To correlate uric acid level with  glomerular  filtration rate in 
normoalbuminuric & microalbuminuric patients with type 1 diabetes. 
 
 To correlate the uric acid level  with hs-CRP  for predicting  
cardiovascular risk  in     normoalbuminuric & microalbuminuric  patients  
with type 1 diabetes. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods   
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MATERIALS &METHODS 
 
 This is a cross sectional case control study and was conducted after 
getting ethical committee approval. The study composed of a total number of 
130 subjects of Type 1 Diabetes mellitus patients attending Diabetology 
outpatient department in Rajiv Gandhi Government  General Hospital, Chennai. 
 
Inclusion Criteria: 
GROUP  A&B : – 
 Type1 diabetic patients 
 Duration of diabetes > 5 yrs 
 Age 10-40 yrs 
 Treatment with insulin. 
 
Exclusion Criteria: 
 Macroalbuminuric  patients 
 End stage renal disease patients 
 Renal transplant patients 
 Type2 Diabetic patients 
 Patient with acute illness; inflammation 
 Patients with cardiac ailments. 
 
Patients  were selected after doing urine dipstick to rule out proteinuria. 
Cases were  divided in to two groups based on Urine albumin creatinine 
ratio.(UACR). 
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Group1: 
 65 Type 1 Diabetic patients with  normoalbuminuria.(UACR<30mg/g of 
creatinine). 
 
Group2: 
 65 Type 1 Diabetic patients with Microalbuminuria.(UACR 30-300mg/g 
of creatinine.) 
 
Urine sample collection: 
Urine sample was collected after giving instructions  to the patient. 
 First voided sample was discarded. 
 Early morning mid-stream urine was collected. 
 Urine for albumin creatinine ratio was  analysed on the same day. 
 
Blood sample collection: 
 Blood was collected after 8-12 hrs of overnight fasting. 
 About 5mL of venous blood  was collected from  antecubital vein after 
aseptic precautions  and transferred in to 2 tubes and the investigations 
performed as per the following table. 
 
Tubes Anticoagulant Amount of blood Investigations 
Tube1 EDTA 3mL 
Fasting Plasma 
Glucose,HbA1c,Fasting 
Plasma Lipid profile. 
Tube2 --- 2mL 
Serum Creatinine, 
Protein, albumin, Uric 
acid ,hs-CRP. 
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 The blood samples were  analysed with in 4 hrs of sample  collection and 
were analysed by the  following methodologies. 
 
Estimation of Urine albumin concentration: 
 Method: Latex agglutination method/Immunoturbidimetry. 
 Kit from  Bio systems Instruments &Reagents.  
 
Principle:  
 Albumin in the urine sample causes agglutination of the latex particles 
coated with anti human albumin. The agglutination of the particles is directly 
proportional  to the concentration of albumin and can be measured by 
turbidimetry. 
 
Composition: 
Reagent A: 
Sodium azide 0.95g/L 
Borate buffer 0.1mol/L,PH-10.0 
 
Reagent B: 
 Sodium azide 0.95g/L 
 Suspension of latex particles coated with anti-human albumin antibodies. 
 
Preparation of Reagents: 
 Smaller working reagent volumes were  prepared by mixing 1 mL of 
Reagent B with 4mL of Reagent A.(1:4 ratio)and mixed thoroughly. 
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 Albumin standard: Reconstitute with 1mL of distilled water. 
 
PROCEDURE: 
 Instrument &Working reagent were brought to 37c.After being 
standardised  with the  given  microalbumin standard solution . 7µL of sample 
was added to 1mL of working reagent and mixed well .The absorbance was 
measured after 10 sec (A1) and  2mins (A2) at 540nm. 
 
Calculation: 
Albumin concentration in the sample was calculated by 
concentration of albumin(mg/L)= ΔA of test 
                                                      -------------   * concentration  of Std. 
                                                      ΔA of std 
 
Urine albumin mg/dL= albumin in mg/L*10. 
 
Reference value: 
 Urine albumin=up to 15mg/L. 
 
Estimation of Creatinine concentration in the urine sample: 
 Method: Modified Jaffe’s  method. 
 
Principle: 
 Creatinine  in the  urine sample reacts with alkaline picrate to form an 
orange yellow colour  creatinine  picrate. The intensity of the colour is directly 
proportional  to the  creatinine concentration and is measured  
spectrophotometrically at 500-520nm. 
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Working Reagent Preparation: 
 Equal volumes of Reagent1 &Reagent 2 was mixed & kept aside for 
15mts. 
 
Preparation of sample:  
 Dilute urine samples with 1:10 dilution. 
 Reagent1 : Picric acid-25.8mmol/L 
 Reagent2 : Sodium hydroxide-95mmol/L. 
 
Procedure: 
 Analyser was calibrated  using the creatinine standard provided with the 
kit.50µL of diluted sample was added to 500µL of working reagent mixed well 
and the  reading obtained from the semi automatic analyser was multiplied by 
the dilution factor to get correct concentration. 
 
Calculation: 
Creatinine(mg/dL)=ΔA of Test 
                                 ---------------* Concentration of  Std. 
                                ΔA of std 
 
Creatinine(g/dL)=Creatinine(mg/dL)/1000. 
 
Reference  range: 
 Adult Male-14 to26 mg/kg/day. 
 Adult Female:11-20mg/kg/day. 
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Urine albumin creatinine Ratio: 
UACR=Urine albumin(mg/dL) 
             ------------------------------ 
              Urine  Creatinine(g/dL) 
UACR=mg/g of creatinine. 
 
 After classifying  the patients based on UACR  in to 2 groups, following 
analytes  were estimated. 
 
Estimation of serum uric acid: 
Method: uricase, Endpoint assay. 
 
Principle: 
 Uric acid in the presence of uricase is oxidised to allantoin. Peroxidase 
reacts with H2o2catalyses the oxidative coupling of 4AAP with TOOS  to form 
Quinoneimine complex and the intensity of colour is directly proportional to the 
concentration of uric acid in the sample. The absorbance of final colour is 
measured at 546nm  & 670nm. 
 
                                        Uricase  
Uric acid+o2 + H2o                              Allantoin+co2+ H2o2  
                                          Peroxidase 
TOOS +4AAP+2 H2o2                                             Quinoneimine  dye+4 H2o. 
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Procedure: 
 Analyser was calibrated using the given standard concentration of 6 
mg/dL. To 1mL of reagent,  25 µL of sample was added  and after 5mts  the 
absorbance was measured spectrophotometrically  at 546 &670nm. 
 
Calculation: 
Uricacid(mg/dL)=Absorbance of test 
                                                                x concentration of std. 
                              Absorbance of std. 
 
Reference Values: 
 Men  : 3.6-7.7mg/dL. 
 Women : 2.5-6.8mg/dL. 
 
Estimation  of hs-CRP: 
 Method: Quantitative sandwich enzyme immunoassay 
 Kit from  Calbiotech.  
 
Principle: 
 A monoclonal antibody specific for CRP  has been precoated  on to a 
microplate. 
 Samples and anti CRP -HRP conjugate were pipetted in to the wells &  
CRP present in the sample  is bound by the immobilised antibody. 
 Anti CRP second antibody  then binds to CRP. After  washing away any 
unbound substances & HRP conjugate ,a substrate  solution is added to 
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the wells and colour develops which is proportional to the concentration 
of CRP in the samples. 
 The colour development is stopped & intensity of colour is measured at 
450nm 
 .Reagent composition: 
1.CRP  microplate-96  microwells coated with CRP  monoclonal 
antibody. 
2.CRP enzyme conjugate -12mL of monoclonal antibody against CRP  
conjugated to HRP. 
3.CRP standard-0.25mL with preservatives. 
4.Sample diluent-50mL with preservatives. 
5.Wash buffer  concentrate-25mL of 20 fold concentrated  solution with 
preservatives. 
6.TMB subsrate-12mL 
7.Stop solution-12mL. 
 
Working reagent preparation: 
 Wash buffer:(1x wash Buffer)-Wash Buffer 1 fold concentrate was 
prepared by diluting 25 mL of 20 fold concentrate to 475 mL of distilled water. 
 
Sample preparation:  
 Samples were diluted using sample diluent in the ratio 1:100.(5µL of 
samples to 495µL of sample diluent.) 
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Assay procedure: 
 Reagent & Sample preparation was done.. 
 Allow the reagent to stand at room temperature(18-25c). 
 Add 10µL  of std, diluted sample & control  per well. 
 Add 100µL of enzyme conjugate to all wells. Mix well. 
 Incubate for 60 mins at room temperature. 
 Empty the wells. Wash well three times with 300 µL of wash buffer. Blot 
on absorbent  paper towels. 
 Add 100µL 0f TMB substrate to all wells. 
 Incubate for 15 mins  at room temperature. 
 Add 50µL of stop solution to all wells. 
 OD of each well was determined  with in 15 mins after adding  the stop 
solution using  microplate reader set at 450 nm. 
 
Calculation: 
 A standard  curve  was constructed  by  plotting  the  concentration  on 
the x-axis  and  the mean absorbance of each  standard  on the Y-axis  and  a best  
fit  curve  was  drawn  through  points on the  graph. 
 
 The  following  table  shows  the  absorbance (OD) of each  std and the  
concentration  of CRP  in the sample was  obtained  based  on this  absorbance. 
Final concentration of the sample was obtained by multiplying with the  dilution 
factor. 
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S.No Concentration of std(mg/L) Absorbance(OD) 
1. 0 0.0818 
2. 0.005 0.5487 
3. 0.01 0.8336 
4. 0.025 1.4297 
5. 0.05 2.2694. 
6. 0.1 2.6793. 
 
 
 
 
Serum Creatinine: 
Method: Modified Jaffe’s method. 
Principle: 
 Creatinine reacts with alkaline picrate  to form an orange yellow  colour 
creatinine picrate. The intensity of the colour is directly  proportional to the 
creatinine concentration and is measured spectrophotometrically at 500-520nm. 
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Reagents: 
R1-Sodium hydroxide-240mmol/L 
R2-Picric acid-26mmol/L 
 
Procedure: 
 Automated chemistry analyser  ERBA 640  was first calibrated using the 
creatinine calibrator  traceable to Isotope dilution mass spectrometry(IDMS) . 
Results were calculated  automatically by the instrument. 
 
Reference values: 
 Males  : 0.7-1.4mg/dL. 
 Females : 0.6-1.2mg/dL. 
 
Estimated GFR(eGFR) 
eGFR is calculated using serum creatinine by CKD-EPI formula  as follows. 
eGFR=141*min (Serum Cr/K,1)α *Max (Serum Cr/K,1)-1.029 *0.993age *(1.018  
if  female)*1.159  if  Black. 
(a)  ߢ = 0.7 (female) or 0.9 (male); 
(b)  ߙ = −0.329 (female and SC ≤ 0.7mg/dL),  
 α=−1.209 (female and SC >0.7mg/dL); 
(c)  ߙ = −0.411 (male and SC ≤ 0.9mg/dL),  
 α=−1.209 (male and SC >0.9mg/Dl 
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Estimation of Plasma Glucose: 
 Method: Glucose oxidase -Peroxidase method(GOD-POD), End point 
assay. 
 
Principle:  
 Glucose in the sample in the presence of Glucose oxidase ,oxidises to  
Gluconic acid & hydrogen peroxide, which in turn reacts with 4-aminoantipyrine  
in the  presence  of peroxidase  enzyme  to form a  coloured quinoneimine 
complex. The intensity of colour is proportional to the concentration of  glucose 
in  the sample. 
 
                                 Glucose oxidase 
Glucose+o2+H2O                                       Gluconic acid+H2o2. 
                                          Peroxidase 
H2o2+Phenol+4AAP                                 Quinoneimine dye+2H2O. 
 
Procedure: 
 After being standardised  with   standard  Glucose solution of 100 
mg/dL,10µL of plasma   was added to1 mL of working reagent & incubated at 
37c for 15 mts and   the absorbance  was measured at 505nm. 
 
Calculation: 
 Glucose mg/dL=   Absorbance of test 
                    ------------------------      x Concentration of standard. 
                 Absorbance of Standard. 
 
Reference interval: Fasting  plasma Glucose=70-100 mg/dL. 
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Estimation of Urea: 
 Method: UV-SLR, Fixed time Kinetic assay. 
 
Principle:  
 Urea is  hydrolysed in the presence of water & urease to produce 
ammonia & co2.The ammonia produced combines with α-oxoglutarate& NADH 
in the presence of glutamate dehydrogenase to yield  glutamate  & NAD. 
 
Reagent composition: 
Reagent1 : Buffer reagent. 
Reagent 2 : Enzyme reagent. 
Urea standard: 50mg/dL. 
 
Procedure: 
 After being standardised  with 50mg/dL of urea standard solution, Serum 
samples were analysed. To 1mL of working reagent  10µL of serum. was added. 
Mixed well & the absorbance was read after 30 sec  and  60 secs at 340nm. 
 
Concentration of Urea(mg/dL) =      ΔA of test 
                                                     -------------------   x 50 
                                                     ΔA of  standard 
 
Reference range: 15-50 mg/dL. 
Reference interval:0.2-10 mg/L.  
 
Estimation  of serum protein: 
 Method: Biuret method, Endpoint assay. 
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Principle: 
 Protein in serum sample  reacts  with copper salts  in an alkaline  medium  
forming  a purple coloured  complex. The intensity of  colour is  directly 
proportional to total protein concentration that  can be  measured 
spectrophotometrically  at 540nm. 
 
Procedure: 
 Analyser  was  calibrated using the given  protein standard  of  6g/dL  
concentration. To 500µL of reagent  10µL of sample was added  and incubated  
for 10 mts at 15-30oc. The readings  were measured against reagent blank at 
540nm. 
 
Calculation:  
Concentration of Protein(g/dL)=Absorbance of test 
                                                     ------------------------ x concentration of  std 
                                                      Absorbance of std 
 
Reference interval:adults:6-8g/dL. 
 
Estimation  of serum albumin: 
 Method: Bromocresol green, End point assay. 
 
Principle: 
 Albumin acts as a cation ,binds to anionic dye  bromocresol green at pH 
3.68 forming a green coloured complex. The  colour  intensity is directly 
proportional to concentration of albumin in sample.  The absorbance of final 
colour is measured at 578nm. 
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Procedure: 
Analyser  was  calibrated using the given std concentration of 4g/dL. 
To 1 mL of reagent   10µL 0f sample was added .Mixed well & after 5 mins the 
absorbance was measured  spectrophotometrically  at 578nm. 
Calculation 
Albumin(g/dL)=Absorbance of test 
                            ----------------------x concentration of std. 
                           Absorbance of std. 
 
Reference interval: Adult:3.5-5g/dL. 
Estimation of HbA1c:(Bio Rad D-10 Analyser). 
 Method: Ion exchange high performance liquid chromatography. 
 
Principle: 
 In  HPLC, the samples are automatically diluted on D-10 and injected in 
to the analytical cartridge. The D-10 delivers a programmed buffer gradient of 
increasing ionic strength to the cartridge, where the hemoglobins are separated 
based on their ionic interactions with the cartridge material. The separated 
hemoglobins then pass through the flowcell of the filter photometer, where 
changes in the absorbance at 415 nm are measured.  
 
          Two level calibration is used for quantitation of HbA1c values. A sample  
report & chromatogram are generated  for each  sample. The A1c peak is shaded. 
This  area is calculated using an exponentially modified Gaussian (EMG) 
algorithm that excludes labile A1c & Carbomylated peak areas from the A1c 
peak area. 
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         ADA & IFCC  issued a consensus statement on the world wide 
standardisation of HbA1c measurement. They recommended the use of IFCC SI 
units(mmol/mol). 
Master equation for designated comparison method (DCM) 
NGSP%    =(0.09148x IFCC )+2.152. 
Reportable range: 
NGSP%              :3.8 -18.5 
IFCC(mmol/mol):18-179. 
                         
Estimation of Total Cholesterol:  
 Method: Cholesterol esterase-Cholesterol Oxidase, End point assay. 
 
Principle: 
 Cholesterol esterase  hydrolyses  Cholesterol ester to Cholesterol .It is 
acted upon by Oxidase  to form cholestenone  and hydrogen peroxide. It reacts 
with aminoantipyrine  and phenol  to give  pink coloured complex  and its 
optical density measured at 540nm. 
                                         
                                 
                                        Cholesterol esterase 
 
Cholesterol ester+H2o                                              cholesterol +Fatty acids. 
                                    Cholesterol Oxidase   
Cholesterol+O2                                                                               Cholest-4-en-3-one+H2o2  
                                           Peroxidase 
2H2o2   +4AAP+                                              PhenolQuinoneimine dye+4 H2o. 
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Procedure: 
The  semiautoanalyser was first calibrated using Cholesterol standard of 200 
mg/dL. 10µL of  Plasma was pipetted in to 1mL of working reagent,&  
incubated at 37oc for 5 minutes.  The absorbance was measured at 540nm. 
Calculation: 
 
Cholesterol(mg/dL)=Absorbance of Test 
                                    -------------------------x Concentration of Standard.(mg/dL) 
                                    Absorbance of Std 
 
Reference interval:150-260mg/dL. 
 
Estimation of Triglycerides: 
 Method: Glycerophosphate oxidase -chlorophenol Amino 
phenazone(GPO-PAP) method, End point assay. 
 
Principle: 
 Triglycerides in the sample are hydrolysed by Lipoprotein Lipase to give 
glycerol and Fatty acid. Glycerol is then acted upon by glycerol kinase to form 
glycerol-3-phosphate.Which on action by oxidase  converted in to  DHAP & 
hydrogen peroxide. Hydrogen peroxide reacts with 4-aminoantipyrine(AAP) to 
give  pink coloured complex. The intensity of colour is related to concentration 
of triglyceride  in the sample. 
                          Lipoprotein Lipase 
TGL+H2o                                                  Glycerol+ Free Fatty acids. 
                         Glycerol Kinase 
Glycerol+ ATP                                       Glycerol-3-Phosphate +ADP 
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                                            Glycerol-3-phosphate oxidase 
Glycerol-3-phosphate+o2                                                                                       DAP+ H2o2                                                        
                                         Peroxidase 
H2o2  +4AAP+ TOOS                                       Quinoneimine dye+2 H2o 
 
Procedure:  
 The analyser was first   calibrated  with Triglyceride standard(200mg/dL). 
10 µL of sample was mixed with 1 mL of reagent and  incubated  for 10 minutes 
at 37oc.  the absorbance was measured  at 540nm. 
 
Calculation: 
Triglycerides(mg/dL)= Absorbance  of Test 
                                                                             x  concentration of Std(mg/dL) 
                                   Absorbance of  Standard 
 
Reference Values: 
 Males:60-165mg/dL 
 Females:40-140mg/dL. 
 
Estimation of HDL-Cholesterol: 
 Method: Phosphotungstic acid method, Endpoint  assay 
Principle: 
 Phosphotungstate  precipitates  Chylomicrons, LDL and VLDL  in the 
presence of divalent  cations .The supernatant ,which contains HDL cholesterol 
remains unaffected and is estimated using cholesterol reagent. 
 
                  Phosphotungstate 
Plasma                                         HDL+(Chylomicrons, LDL, VLDL precipitate) 
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Precipitating reagent: 
 Phosphotungstic acid-2.4mmol/L. 
 Magnesium chloride-40mmol/l. 
 
Procedure: 
1)Precipitation: 
 Precipitation of LDL, VLDL, Chylomicrons. 
 500µL of precipitating reagent & 250µL of sample  was mixed well and 
allow to stand for 10 mts at  room temperature. Centrifuged for 10 minutes at 
4000 r.p.m  to get a clear supernatant.  Concentration of HDL cholesterol was 
determined  by  using cholesterol reagent. 
 
2)Estimation with Cholesterol reagent: 
 50µL of Supernatant  was pipetted in to 1000µL of Cholesterol working 
reagent and incubated for 10 minutes at 37oc. Read the absorbance at 505 nm. 
Calculation: 
HDL Cholesterol=Absorbance of test  
                            --------------------------x concentration of Std x 2(mg/dL) 
                              Absorbance of Std 
(2 is the dilution factor due to deproteinisation  step). 
 
Reference Values: 
 In Male:35-55mg/dL 
 In Females:45-65mg/dL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical Analysis   
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                                         STATISTICAL ANALYSIS: 
 Data was analysed using SPSS software version 16.0 and p value less 
than 0.05  was considered as statistically significant. 
 Age, Duration of Diabetes, BMI, Total cholesterol, HbA1c, Uric acid, 
eGFR, hs-CRP were compared between study groups by Student t-test. 
 Gender was analysed by Chi square test 
 One way ANOVA was done to compare more than two variables in the 
same group & between two groups . It was carried out to compare eGFR  
between Normoalbuminuric & Microalbuminuric type 1 Diabetic 
patients. 
 Correlation of Parameters namely hs-CRP, eGFR, with uric acid  were 
found out by Pearson correlation analysis. 
 To find out the correlation between uric acid &eGFR in the presence of 
HbA1c, partial correlation was used. 
 Multiple  regression  analysis  was  performed to evaluate the 
mathematical relationship between eGFR and other variables (Age, 
duration, Gender, HbA1c, Cholesterol, BMI & Uric acid) in  
Normoalbuminuric & Microalbuminuric  Type 1 Diabetes. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results   
BMI fasting PG Urea creatinine uricacid cholester TGL HDL Hba1c S.Protein S.albumin U.Albumin U.Creatinine urine ACR hsCRP
eGFR 
(CKD-EPI)
(Kg/m^2) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) % (g/dL) (g/dL) (mg/L) (mg/dL) (mg/g) (mg/L) (ml/min)
1 24 F 12 139 49 25.361006 N 159.4 15 0.6 1.2 143 45 36 8.9 5.6 3.3 1.8 75.2 2.39 0.6 128
2 28 M 5 142 49 24.300734 N 98 40 1.3 6.8 236 118 45 6 6.7 4.5 1.8 66.6 2.7 0.2 74.3
3 22 F 5 154 50 21.082813 N 105 26 0.7 2.35 79 74 15 7.1 6.8 3.9 0.9 29.2 3.08 0.3 123.4
4 21 M 5 149 47 21.170218 N 68 18 0.8 5.6 140 73 44 6.3 6.3 2.8 1.5 42.3 3.54 0.2 127.7
5 26 F 8 151 51 22.36744 N 160.2 33 0.7 2.6 264 149 42 10.3 6.3 3.4 5.4 138.8 3.89 0.8 120
6 31 F 6 160 45 17.578125 Y 151 13 0.6 2.4 87 59 45 7.6 5.7 3.7 0.9 22 4.09 4 121.8
7 40 M 18 169 61 21.357796 Y 144 29 0.9 4.5 156 84 47 7.7 6.5 4 0.9 22 4.09 0.4 111.7
8 16 M 5 140 38 19.387755 N 80.8 28 0.7 3.8 100 98 38 15.3 6 4 1 23.8 4.2 1.35 139.7
9 25 F 9 155 63 26.222685 Y 183.4 32 0.8 2.58 133 115 40 8 6 4.6 2 45 4.44 0.5 102.8
10 17 F 10 144 35 16.878858 N 229 30 0.8 4.32 231 98 26 7.1 6.4 4.4 1.01 20 5.05 1.8 108.7
11 24 M 16 157 60 24.341758 N 184.9 29 0.8 4.3 168 80 51 10.1 6.5 4.2 6 118.4 5.06 1.91 125
12 40 F 25 140 37 18.877551 N 231 30 0.9 6.7 167 135 66 9 5.9 3.9 1.2 20.8 5.76 1.4 80.2
13 19 M 10 152 54 23.372576 N 70 30 0.9 7.7 201 83 21 9.2 6.8 4.4 8 122.2 6.54 2.8 118.3
14 40 M 15 168 61 21.612812 N 121 23 0.9 2.9 164 150 34 10.3 6.9 3.8 6.1 92.8 6.57 15.41 106.5
15 23 M 6 159 60 23.733238 N 135.2 26 0.7 5 127 39 40 9.5 6.1 4.3 5.2 76.6 6.78 2.75 130.2
16 16 F 2 135 40 21.947874 N 229.2 27 0.8 5.9 217 78 51 10 6.5 4.4 4.3 62.8 6.84 2.2 109.5
17 34 F 14 151 49 21.490286 N 86 14 0.8 3.8 119 53 45 7 5.9 3.3 5.4 63.6 8.4 1 96.5
18 34 F 19 155 54 22.476587 N 55.5 27 0.6 3.3 174 82 37 6.9 6.4 4.1 4 47.2 8.47 1 119.3
19 30 M 12 148 54 24.653031 Y 280 37 0.8 3.4 86 238 34 7.7 6.4 4 9.1 107 8.5 1.3 119.9
20 26 M 5 159 74 29.270994 Y 71 37 0.9 3.82 150 74 50 7.4 5.9 4 2.1 24.4 8.6 0.6 117.5
21 37 F 20 156 62 25.47666 N 66.8 16 0.7 2.1 227 127 55 7.9 5.8 4 1.9 22 8.63 4 111
22 34 F 15 153 41 17.514631 N 176 24 0.5 3.3 124 47 35 7.1 6.3 4.6 3.1 34.6 8.95 1.6 126.7
23 35 F 14 154 65 27.407657 N 107 23 0.5 3.2 100 135 29 8.8 6.3 4.4 2.3 25 9.2 0.1 125.8
24 40 M 15 155 51 21.227888 N 119 25 1.3 8.4 142 126 37 7.3 6.2 4 6.5 65.5 9.92 12.7 68.3
25 16 F 9 132 43 24.678604 N 338 33 0.8 2.64 68 125 35 10.7 6.7 5.4 6.9 69.1 9.98 1 109.5
26 17 F 5 161 46 17.746229 N 68 34 0.7 3.8 218 97 53 10.4 6.5 4 2.5 24.3 10.28 3 127.8
27 40 F 10 155 56 23.309053 N 93.5 24 0.6 3.1 135 40 148 7.1 6.4 4.2 2 18.8 10.6 2.4 114.4
28 40 M 25 151 45 19.735976 Y 72.5 33 0.8 4.9 119 88 17 6.9 5.8 2.7 4.14 30.8 10.89 8.3 111.7
29 29 F 5 154 48 20.239501 N 93.3 28 0.6 3.6 134 57 36 7 6.5 3.7 13.6 122.3 11.12 0.8 123.6
30 37 M 23 154 64 26.986001 N 414 11 0.8 1 107 94 19 9.3 7.4 4.4 2.62 23.4 11.19 5.9 114.1
31 39 F 15 158 53 21.230572 Y 98 41 0.9 7.8 132 98 40 6.5 6.3 3.5 2.3 19.9 11.5 13.8 80.8
32 40 M 26 161 59 22.761468 Y 185 50 1.1 5.25 94 210 25 7.5 6 2.62 2.62 22.6 11.59 8.2 83.5
33 33 F 20 146 55 25.802214 N 212.8 18 0.8 3.4 130 55 54 7 6.3 2.6 2.62 22.5 11.64 0.5 97.2
MASTER CHART  OF NORMOALBUMINURIC TYPE 1 DIABETIC PATIENTS
CASES AGE GENDER DURATION HT WT HYPER T
BMI fasting PG Urea creatinine uricacid cholester TGL HDL Hba1c S.Protein S.albumin U.Albumin U.Creatinine urine ACR hsCRP
eGFR 
(CKD-EPI)
(Kg/m^2) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) % (g/dL) (g/dL) (mg/L) (mg/dL) (mg/g) (mg/L) (ml/min)
34 25 F 8 160 55 21.484375 Y 113.9 30 0.7 3.54 177 134 34 9.6 6.3 3.5 5.9 50.4 11.7 0.9 120.8
35 18 F 10 135 42 23.045267 N 90.6 29 0.5 2.68 207 123 37 9.7 6.3 4.4 3.01 23.6 12.75 24.8 141.8
36 18 F 5 151 51 22.36744 N 86 34 0.6 3 102 125 40 6.7 5.6 4 6.9 52.8 13.06 0.8 133.5
37 30 M 15 160 59 23.046875 N 64 32 1 6 188 137 38 6.7 6.6 4 6.5 50 13.2 0.3 100.5
38 37 F 25 151 51 22.36744 N 77.4 43 0.6 3.94 188 83 34 9.4 5.7 3.2 4.4 32 13.75 1.1 116.8
39 35 M 25 159 58 22.94213 Y 193 43 1 3.8 128 130 29 9 5.7 4.2 13 90 14.44 0.3 97.1
40 21 F 8 148 51 23.283419 N 225 40 0.8 2.8 63 25 46 6.3 6.1 3.4 4.8 31.8 15.09 0.9 106
41 16 M 6 169 38 13.304856 N 87.8 31 0.8 4.5 96 110 38 8.6 5.8 3 19.8 128.4 15.42 1.5 132.3
42 15 F 5 152 46 19.909972 N 109 38 0.8 2.28 147 82 30 9.5 5.9 4 3.06 19.6 15.61 1.3 110
43 40 F 15 156 61 25.065746 N 83 31 0.8 4 138 88 22 7.4 6.8 3.5 6.6 40.5 16.29 1.2 92.5
44 26 M 17 163 47 17.689789 Y 50 64 1.6 1.6 139 92 40 6.2 6.5 4 4.24 25.7 16.49 9.3 58.6
45 40 M 16 146 50 23.456558 Y 105 19 1 4.3 233 68 59 6.2 6.5 4.2 5.54 32.85 16.86 5 93.7
46 24 M 17 170 51 17.647059 N 297.4 26 0.8 3.6 147 55 46 9.4 6.5 5.3 3.6 21.3 16.9 4.8 125
47 29 M 9 174 58 19.157088 N 132 57 0.7 3.5 98 100 30 8 5.2 3 3.94 21.9 17.99 0.2 127.5
48 30 F 14 156 65 26.709402 N 116 101 0.5 1.7 140 78 41 8 7.5 4.1 8.4 44.7 18.79 0.4 130.3
49 35 F 13 154 74 31.202564 N 283 31 0.8 2.39 227 66 41 10.7 6.2 4 11 54 20.37 0.2 95.8
50 36 F 10 154 62 26.142688 N 83 23 0.6 2.7 112 100 25 10.1 5.7 4 9.6 46.8 20.51 4.7 117.6
51 23 F 14 155 64 26.638918 N 89 43 0.8 2.9 121 79 15 8.7 5.6 2.9 15 70.5 21.27 0.6 104.3
52 23 M 5 140 58 29.591837 N 87 43 0.9 4.14 107 77 55 7 6.5 4 9.8 45.6 21.49 0.3 120
53 28 M 12 164 50 18.590125 N 226.5 40 1 4.72 68 71 24 7.8 6 3.5 8.2 37.2 22.04 0.4 102
54 17 F 6 140 45 22.959184 N 191.3 19 0.6 2.8 117 47 53 8.5 5.9 4.4 18.2 81.6 22.3 4.5 134.4
55 24 M 5 140 55 28.061224 N 298.5 29 0.8 3.3 115 64 46 8.7 5.9 3.9 4.62 19.9 23.21 0.3 125
56 17 F 10 150 40 17.777778 N 184 36 0.7 1.88 102 239 23 10.6 5.9 4 11 46 23.91 1.8 127.8
57 14 M 5 138 30 15.752993 Y 126 42 0.6 4.43 185 95 49 11.2 8.4 4.3 4.14 17.3 23.93 2 151
58 21 F 11 159 55 21.755469 Y 163.2 36 1.1 3.31 170 132 46 8.9 6.3 4.4 10.6 43.9 24.1 11.8 71.9
59 40 M 18 148 46 21.00073 Y 60 27 0.8 4.6 219 145 36 7 6.5 4.2 5.4 22.2 24.32 1.3 111.7
60 32 F 7 144 44 21.219136 Y 136.8 34 1 4.9 162 69 53 5.2 6.5 3.6 21.3 83.7 25.44 0.62 74.7
61 23 M 5 172 57 19.267171 N 189.8 45 1.1 3.5 227 167 28 12.2 5.6 4.2 6.04 21.9 27.59 18 94.1
62 22 F 11 147 49 22.675737 Y 254.7 18 1.2 4.5 215 160 39 9.3 6.6 4 12.1 43.8 27.62 4.48 64.3
63 34 M 7 169 64 22.408179 N 157.6 33 0.9 6.1 226 85 60 8.6 6.5 4.2 13.4 48 27.91 4.34 111
64 24 F 7 147 37 17.122495 N 123.2 15 0.7 7.1 136 50 52 9.3 5.1 3 6.23 21.6 28.84 2.7 132.1
65 37 M 10 156 54 22.189349 N 333 24 1.2 5 182 37 35 9.6 6.5 4.1 9.7 33.1 29.3 0.49 76.8
WT HYPER TCASES AGE GENDER DURATION HT
BMI fasting PG Urea creatinine uricacid cholester TGL HDL Hba1c S.Protein S.albumin U.Albumin U.Creatinine
urine 
ACR
hsCRP
eGFR 
(CKD-EPI)
(Kg/m^2) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) % (g/dL) (g/dL) (mg/L) (mg/dL) (mg/g) (mg/L) (ml/min)
1 15 M 10 139 49 25.36101 N 191.3 18 0.7 1 104 62 29 7.9 5.9 3 38.4 126.7 30.3 0.3 140.7
2 38 F 10 155 57 23.72529 Y 50 31 1.1 1.6 139 65 48 8 6.4 3.7 7.8 24.2 32.23 1.2 63.8
3 18 F 12 140 39 19.89796 N 513 23 0.7 2.4 263 126 68 11.9 6.2 3.5 6.3 19.2 32.8 2.4 126.9
4 40 F 15 139 54 27.94886 N 206 26 0.8 3.4 206 114 56 9.2 6.5 4.3 13.18 39 33.79 8 92.5
5 38 F 6 148 52 23.73996 N 60 33 0.9 3.28 174 87 30 5.9 5.7 3.4 9.3 24.7 37.65 21.9 81.4
6 27 M 9 156 45 18.49112 Y 93.6 19 0.8 5.3 183 88 29 7.5 6.7 4.1 33.9 87.3 38.83 4.65 122.4
7 30 M 5 166 52 18.87066 N 158.7 48 0.9 4.41 210 199 20 13 5.2 3.4 15 36 41.66 7.1 114.2
8 40 M 25 149 57 25.67452 Y 185 43 1 5 200 135 35 9.4 5 3.2 11.06 23.8 46.47 2.8 93.7
9 26 F 8 142 49 24.30073 N 122 32 0.8 3.4 87 65 35 7.1 5.3 3.3 9.2 19.4 47.42 1.4 102.1
10 24 F 5 151 45 19.73598 N 68 28 0.9 3.1 188 50 52 10.9 6 4.3 11.4 24 47.5 1.3 89.8
11 15 M 5 159 36 14.23994 N 350 34 0.8 2.5 179 186 51 12.6 6.7 4.5 11.9 24.9 47.79 0.5 133.2
12 14 F 5 132 30 17.21763 N 92 26 0.4 4.07 96 102 20 9 6.1 3.4 12.3 23.9 51.46 2 156.9
13 34 M 12 170 70 24.22145 Y 68 49 1 7.54 98 245 25 6 5.4 3.7 11 21.3 51.64 9.3 97.8
14 23 M 10 156 59 24.24392 Y 138.7 33 1.3 6.5 294 130 38 9.1 4.9 3 52.14 95.4 54.65 8.7 76.9
15 35 F 11 149 59 26.57538 N 66 28 0.6 3 153 96 20 8.3 5 3.5 15.73 28.7 54.8 27.9 119
16 32 M 23 160 55 21.48438 N 84 36 1.2 4.8 205 88 39 9.2 7.2 4.1 22.6 40 56.5 5.2 81.8
17 40 M 20 156 60 24.65483 N 108 60 1.6 6.3 129 99 45 7.9 6 4.6 48.54 85.2 56.97 6.8 53.1
18 17 F 7 139 35 18.115 Y 77.6 12 0.7 5.5 158 168 36 5.8 6.4 3.3 10.5 18 58.33 17.5 127.8
19 30 F 9 149 75 33.78226 N 206.8 20 0.7 1 187 63 30 9.8 5.9 4 13.3 21.5 61.86 3.3 116.6
20 30 M 10 154 50 21.08281 Y 117 47 1 5.3 138 125 40 10 5.6 2.9 185.4 299.1 61.98 2.4 100.5
21 40 M 24 150 55 24.44444 Y 64 47 0.8 5.8 172 132 39 7.4 4.7 3.2 16.7 26.5 63.01 5.9 111.7
22 21 M 5 170 85 29.41176 N 265.7 24 0.7 5.5 183 110 80 9.8 8.2 3.8 59.39 91 65.26 3.8 134.9
23 27 M 7 161 60 23.14726 N 64.8 17 0.9 4.1 165 76 58 7.4 6.5 3.6 14.4 21.8 66.05 0.6 116.6
24 39 M 24 171 64 21.88708 Y 151.5 45 1 5 170 100 37 8.2 6.6 4.3 94.4 138.8 68.01 1.61 94.4
25 22 F 5 150 50 22.22222 N 67.9 36 0.7 3.8 199 145 36 12.1 5.5 3.7 77.7 104.1 74.63 6.9 123.4
26 32 M 17 167 58 20.79673 N 197 41 0.8 5 173 56 34 8.4 5.6 4.3 40.5 53.2 76.12 17.4 118
27 28 F 10 140 34 17.34694 N 83.3 29 0.9 3.2 152 52 52 8.1 5.9 3 15.63 20 78.15 17.2 87.3
28 29 M 7 175 106 34.61224 Y 198.9 23 1.3 4.3 130 81 35 8.7 6.8 4.1 102.4 112.2 91.26 11.8 73.7
29 23 F 12 158 58 23.23346 N 169 25 0.7 4.58 138 85 49 6.6 5.7 4.2 20 21.8 91.74 19.9 122.5
30 35 M 16 160 57 22.26563 Y 92.5 28 0.7 3.1 176 155 26 9.1 6 4.6 32.96 35 94.17 14.7 122.3
31 26 F 20 154 55 23.19109 N 227.5 33 0.6 3.97 165 78 33 8.1 5.6 4.2 26.24 26.8 97.91 1.7 126.2
32 40 M 15 152 50 21.64127 Y 137 50 1 5.1 125 65 42 8.4 5.3 3 78.3 78.6 99.61 3.1 93.7
WT
MASTER CHART  OF MICROALBUMINURIC TYPE 1 DIABETIC PATIENTS
HYPER TCASES AGE GENDER DURATION HT
BMI fasting PG Urea creatinine uricacid cholester TGL HDL Hba1c S.Protein S.albumin U.Albumin U.Creatinine
urine 
ACR
hsCRP
eGFR 
(CKD-EPI)
(Kg/m^2) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mg/dL) % (g/dL) (g/dL) (mg/L) (mg/dL) (mg/g) (mg/L) (ml/min)
33 40 M 20 160 76 29.6875 Y 81 28 1.1 6.6 177 123 53 8.5 5.3 3.4 53.96 52.8 102.19 2.61 83.5
34 33 F 20 148 47 21.45727 N 183.8 73 0.9 4.1 191 200 35 10.2 6.2 3 25 22 113.6 23.1 84.3
35 22 F 13 162 65 24.76757 Y 173.8 49 0.9 6.1 150 150 40 7.5 5.2 3.5 51.3 40.2 127.6 10.4 91.1
36 40 F 17 150 43 19.11111 N 81 16 0.5 2.6 202 88 40 9 6.2 3.6 47.1 36.3 129.75 22.9 121.5
37 40 F 20 154 59 24.87772 N 74.6 32 0.8 4.2 178 73 47 7.8 6.3 3.7 29 22 131.81 17.11 97.2
38 32 F 7 160 60 23.4375 N 281.9 20 0.8 5 153 95 32 7.8 5.9 3.4 39 29.5 132.2 25.2 97.9
39 27 M 5 168 58 20.54989 N 203 42 1 5.28 243 75 35 8.6 4.3 3.6 37.9 28.6 132.5 0.9 102.7
40 40 M 26 170 55 19.03114 Y 273 60 1.3 5.28 184 260 19 9.4 5.7 4.2 48 32 137.14 7.6 68.3
41 20 M 4 133 45 25.43954 N 83 57 0.9 2.78 166 245 25 9.2 5.8 3.7 42.6 30.7 138.76 8.7 123
42 28 M 7 160 54 21.09375 N 76 52 1.3 4.9 86 102 42 10 5 3.2 74.2 53.2 139 9.1 74.3
43 39 F 5 149 56 25.22409 Y 254.7 35 0.9 1.89 87 38 20 8.1 5.8 2.7 97.8 68.8 142.15 27.5 80.8
44 37 M 24 147 49 22.67574 N 74 46 0.9 5.1 175 230 29 11.9 5 3.5 82.58 55 150.15 23.6 108.7
45 34 F 16 160 74 28.90625 Y 164 10 0.6 11.7 148 112 58 9.1 6.4 3.6 109.1 65.6 166.31 7.68 119.3
46 24 F 5 152 40 17.31302 N 336 37 0.7 4.53 129 144 40 10.1 5.3 3.5 39.1 23.5 166.38 1 121.7
47 38 M 15 170 64 22.14533 N 79.9 21 0.9 7.5 124 77 32 5.1 5.5 3.7 37.5 22 170.45 12.4 108
48 18 M 5 135 45 24.69136 N 212.5 42 0.8 4.7 191 134 46 9.3 6 3.5 122.4 69.3 176.62 7.8 130.4
49 40 F 18 151 57 24.9989 Y 167 29 0.6 4.75 200 104 60 10 5 3.3 41.9 23.3 179.82 3.1 114.4
50 23 F 13 138 50 26.25499 N 174.4 70 0.8 4.64 183 156 30 6.7 5.6 2.9 51.5 26.5 194.3 10.1 104.3
51 25 M 15 154 56 23.61275 Y 165.7 40 0.9 14 111 65 45 5.9 6.8 3.3 94.9 48 197.7 1.1 118.3
52 24 F 14 154 44 18.55288 N 324 21 0.6 6.24 187 96 25 8.3 4.3 3.6 41.9 19.8 211.6 19.4 128
53 30 M 20 157 60 24.34176 N 526 87 2.5 10.3 151 48 25 6.9 5.6 4.2 64.22 30.1 213.35 14.9 33.2
54 30 M 17 160 64 25 Y 387.7 25 1 4.3 280 121 40 9.6 7.2 3.8 432.9 192.3 225.11 18.8 100.5
55 27 M 20 161 64 24.69041 Y 61 58 1.6 11 213 117 57 11.3 6 3.7 52.47 22.8 230.13 27 58.2
56 40 M 12 163 70 26.34649 Y 52 20 1.1 3.2 168 104 39 10.3 6.3 3 50.7 21.3 238.02 5.6 83.5
57 40 M 25 159 58 22.94213 Y 401 28 1 6.3 194 306 27 9.1 7.3 3.5 89.6 37.2 240.8 14.76 93.7
58 18 F 5 152 43 18.6115 N 242.2 34 0.8 3.3 161 319 23 7.5 5.5 3.7 73.2 29.1 251.54 18.2 108
59 35 F 20 150 49 21.77778 Y 135 381 >20 12.4 35 32 47 7.1 6.7 5.3 149 58.1 256.45 12.1 1.8
60 26 F 10 165 48 17.63085 N 223 20 0.6 4.04 252 134 29 8.5 5.2 3.1 60.42 21.9 275.89 9.6 126.2
61 40 F 27 136 34 18.38235 y 148 77 1.4 6.7 117 58 34 7.7 4 2.9 62.3 22.3 279.37 8.2 47
62 26 F 17 150 43 19.11111 N 183.4 38 1 6.13 162 75 38 8.6 5.66 3.4 94.68 32.9 287.79 14.1 77.9
63 28 M 15 164 49 18.21832 N 183.8 29 0.8 3.9 144 54 40 11 7 3.8 62.36 21.6 288.7 6.2 121.6
64 30 F 5 145 39 18.54935 N 70 41 1 5.1 88 123 35 5.7 5.2 3.3 58 20 290 24.6 75.8
65 36 F 20 155 52 21.64412 N 427.7 32 0.8 3.2 123 128 30 8.4 4.3 3.6 51.3 17.6 291.4 10.8 95.2
WT HYPER TCASES AGE GENDER DURATION HT
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RESULTS 
TABLE1: COMPARISION OF CHARACTERISTICS OF TYPE1 
DIABETICS WITH NORMOALBUMINURIA  AND 
MICROALBUMINURIA 
NS-NOT SIGNIFICANT 
 
*-SIGNIFICANT. 
 
**- HIGHLY SIGNIFICANT. 
 
 
 
 Albuminuria N Mean Std. Deviation p value 
Age 
Normal 65 28.10 8.32 
0.16-NS 
Micro 65 30.12 7.78 
BMI 
Normal 65 22.26 3.50 
0.46-NS 
Micro 65 22.74 3.85 
FBS(mg/dL) 
Normal 65 149.28 80.50 
0.19-NS 
Micro 65 171.98 111.39 
HbA1C(%) 
Normal 65 8.44 1.723 
0.41-NS 
Micro 65 8.69 1.69 
Total 
Cholesterol(mg/dL) 
Normal 65 150.06 49.34 
0.09-NS 
Micro 65 164.49 47.39 
TGL(mg/dL) 
Normal 65 97.49 44.28 
0.04* 
Micro 65 117.13 61.79 
HDL(mg/dL) 
Normal 65 40.52 17.71 
0.39-NS 
Micro 65 38.21 12.25 
Creatinine(mg/dL) 
Normal 65 .81 .21 
0.21-NS 
Micro 65 1.28 3.00 
Albumin(g/dL) 
Normal 65 3.90 .56 
0.003** 
Micro 65 3.62 .50 
Total Protein(g/dL) 
Normal 65 6.25 .52 
<0.001** 
Micro 65 5.81 .79 
UrineACR 
Normal 65 13.64 7.66 
<0.001** 
Micro 65 127.98 81.23 
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 Table-1 shows the data of Age, Body mass index, Fasting plasma  
glucose,  HbaA1c, Total Cholesterol, Triglycerides, HDL-c, Serum creatinine, 
Serum albumin, Total protein, Urine Albumin creatinine Ratio among  
Normoalbuminuric & Microalbuminuric  Type 1 Diabetic patients. 
 
 An insignificant p value was obtained with respect to variables like Age, 
Fasting Plasma Glucose,HbA1c,Total cholesterol, HDLc& serum Creatinine. 
 
A significant p value was obtained for 
i. Triglycerides  in Normoalbuminurics (97.49 ± 44.2) 
&Microalbuminurics (117.13 ± 61.79)  with p value  of 0.04. 
ii. Serum albumin in Normoalbuminurics (3.90±0.56) 
&Microalbuminurics (3.62±0.50) with p value of 0.003. 
iii. Serum Total protein in Normoalbuminurics (6.25±0.52) 
&Microalbuminurics  (5.81±0.79) with p value of<0.001. 
iv. Urine albumin creatinine ratio in Normoalbuminurics 
(13.64+/7.66)&Microalbuminurics (127.98+/81.23) with  p value of 
<0.001. 
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TABLE 2 : COMPARISION OF URIC ACID WITH 
NORMOALBUMINURIA & MICROALBUMINURIA 
 
 
 Albuminuria N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Uricacid 
Normal 65 3.92 1.59 0.20 
Micro 65 4.99 2.48 0.31 
 
p = 0.004 (highly significant) 
 Table 2 Shows the comparison of uric acid between study groups. The 
Mean  Uric acid in Diabetics  with  normo albuminuria  was (3.92+/-1.59) and 
Microalbuminuria  was (4.99+/-2.48).A highly  significant  p value of 0.004 was 
obtained. 
 
BOX & WHISKER PLOT SHOWS THE DISTRIBUTION OF URIC 
ACID IN NORMOALBUMINURIA &MICROALBUMINURIA. 
 
1=Normoalbuminuria,   2=Microalbuminuria,  
                                     o-Outliers,  *-Extreme values.  
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Table:4  :  ANOVA 
 
eGFR 
 N Mean Std. Deviation P value 
1 29 114.58 20.03 
<0.001 
2 29 109.55 17.69 
3 28 107.80 22.72 
4 19 104.12 19.72 
5 23 84.93 32.00 
Total 128 105.07 24.50 
 
P<0.001(highly significant) 
Uric acid concentrations: 
< 3 mg  = 1  
3 to 3.9 = 2 
 4 to 4.9 = 3 
 5 to 5.9 =4 
> 6 mg = 5 
 
 Table 4 :  ANOVA was used to compare the Mean GFR between 2 
groups. The Mean GFR was higher in Normoalbuminuria  than 
Microalbuminuria  and the difference in Mean was statistically significant  with 
a  P value <0.001. 
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TABLE7 :COMPARISION OF hs-CRP BETWEEN 
NORMOALBUMINNURIA & MICROALBUMINURIA 
 
 Albuminuria N Mean Std. Deviation 
Std. Error 
Mean 
hsCRP 
normal 59 1.9939 2.14449 .27919 
micro 38 4.4776 3.05950 .49632 
 
p< 0.001(highly significant). 
 
 Table 7 shows the comparison of hsCRP  between normoalbuminuric& 
Microalbuminuric  Type 1 Diabetic patients..The mean hsCRP in 
Normoalbuminuria was (1.99+/-2.14),Whereas Microalbuminuria was (4.47+/-
3.05) highly Significant P value of <0.001 was obtained. 
 
BOX & WHISKER PLOT  SHOWS THE  DISTRIBUTION OF  hs-CRP  
IN NORMO & MICROALBUMINURIA 
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TABLE:8 
 
Model 
Unstandardized 
Coefficients 
Standardiz
ed 
Coefficients t Sig. 
Collinearity 
Statistics 
B Std. Error Beta Tolerance VIF 
1 
(Constant) 162.04 19.74  8.20 .000   
Age -1.01 .31 -.34 -3.24 .002 .50 1.97 
Gender -4.61 3.85 -.09 -1.19 .233 .85 1.16 
Duration -.082 .38 -.02 -.21 .829 .54 1.84 
BMI -.26 .50 -.04 -.51 .607 .92 1.08 
Hypertension -7.10 4.22 -.13 -1.68 .095 .82 1.21 
Uric acid -3.43 .92 -.30 -3.70 .000 .81 1.22 
HbA1C .58 1.17 .04 .49 .621 .79 1.26 
Cholesterol -.00 .03 -.00 -.07 .942 .90 1.11 
a. Dependent Variable: eGFR 
Age   p < 0.01 
Uric acid  p< 0.001 
Other variables  p> 0.05 
 
 Table 8: shows the Multiple  regression analysis of eGFR with other risk 
factors in Normoalbuminuric &Microalbuminuric  patients with Type 1 
Diabetes. 
 Uric acid remains significantly higher in Microalbuminurics  compared  
to normoalbuminurics  with a p-value of <0.001. 
 There was a significant difference in age groups with a  p value of <0.01. 
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DISCUSSION 
 
 Diabetes is the most common disease causing End stage renal disease(145). 
About 20-30% of Type1 diabetic patients develop nephropathy and 7-10% 
develop coronary artery disease. Generally increase in albumin excretion rate is 
widely accepted as the first clinical sign of Diabetic Nephropathy. 
 
 Recent studies show that reduced Glomerular filtration rate manifests  as 
the primary clinical abnormality of diabetic nephropathy  even before 
microalbuminuric stage and progresses to overt nephropathy. Dyslipidaemia, 
hyperglycemia and systemic hypertension  have additive effects   on the 
progression of microalbuminuria. 
 
 Serum uricacid is a potentially important mediator of renal disease. 
Hyperuricemia increases systemic bloodpressure, proteinuria, renal dysfunction 
& progressive renal scarring via renin angiotensin and COX-2 dependent 
pathway.It is an important risk factor for development of microalbuminuria and 
this risk was independent of age,gender and other risk factors. Hence estimation 
of  serum uric acid  may help to identify individuals with increased risk for 
developing microalbuminuria & CKD. Our study aims to correlate  uricacid  
with  glomerular filtration rate in non proteinuric type 1 Diabetes.                                               
 
 Uricacid also induces endothelial dysfunction by inhibiting nitricoxide 
production and it is a common finding in patients with both cardiovascular 
&renal disease. Diabetes increases  advanced glycated end products which 
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activates  macrophages & upregulates the synthesis of IL-6 &TNF α resulting in 
production of hs-CRP(146).Several studies demonstrated that hs-CRP  predicts 
future coronary events.  
 
 Hence in our study we measured uricacid & hs-CRP for predicting 
cardiovascular  & renal risk in type1 diabetes,so that we would be able to treat 
the patients at an earlier stage  and slow down the progression of renal  & 
cardiovascular disease in type1 diabetes 
 
 In the present study ,we  recruited people in  to two groups 
 Group-I : 65 Normoalbuminurics and   
 Group-II: 65Microalbuminuric type 1 diabetic patients. 
 
 In group -1: Mean  serum uricacid  level was found to be 3.92+/-
1.59.mg/dL which is in normal range. 
 
 In group-II: Mean serum uric acid level was found to be 4.99+/-2.48 
mg/dL which is in high normal range. This result was  similar to the study by 
Krolewski et al(147),   in which they had  showed that majority of  concentration 
of uricacid was in the normal range. but it is higher in microalbuminurics than 
normoalbuminurics . 
 
 Commmunity based study of Japanese adults(148) showed that  
hyperuricemia has strong  predictive   capacity of the risk of renal failure than 
proteinuria.Our study also reflects the same findings. 
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 Similar result have been found in experimental study in Rats.(149). 
 
 Mean GFR was higher in Normoalbuminuric individuals and was in the 
range of 110.40+/-20.30 ml/min and it was lower  in Microalbuminuric 
individuals  which is in the range of 100.25+/-27.12ml/min. 
 
 Although mean GFR in both groups  were in the normal range, 
HyperfiltrationGFR>130ml/min was less  frequently seen in Microalbuminurics 
compared to Normoalbuminuric diabetic patients. 
 
 Conversely moderately impaired renal function with GFR 30-59ml/min & 
mildly impaired renal function  with GFR 60-89 ml/min were more in 
Microalbuminurics than Normoalbuminuric diabetic patients.. 
 
 Variables  like Age, duration, BMI, BP, HbA1c that were associated with 
eGFR in Microalbuminuria & normoalbuminuria were examined by multiple 
regression equations to evaluate their independent contributions.HbA1c, BP and 
BMI measurements did not show  independent effects on eGFR . 
 
 Increasing age &duration of Diabetes  is associated with significant 
Glomerular lesions even in the absence of elevated albumin excretion rate.  In 
our study,there is a statistically significant difference in age groups with p value 
of <0.01 was noted ,but the  duration   was not significant.The possible reason 
for this,may be that Diabetes had manifested  in a much  younger age & the 
duration of  Diabetes was longer ,but it was detected later. As a result of 
this,there is a decrease in eGFR.  
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 Normal range of CRP level in human serum is 0.2-10mg/L. hs-CRP 
ELISA assay  kit has the analytical sensitivity of 0.005µg/mL.Values of  hs-CRP 
>10mg/L on two consecutive tests were excluded,as they were  more likely to be 
due to infections or inflammation(150).  
 
 In our study, the Mean of hs-CRP in Normoalbuminuria was 1.93+/-
2.14mg/L. which was much lower compared toMicroalbuminuria  4.47+/-
3.05mg/mL. In Oxford Regional Prospective study(151), hs-CRP in 
Microalbuminuric Type 1 Diabetic subjects were significantly higher than 
Normoalbuminuric Type 1 Diabetics.Which is similar to the results of our study. 
 
 Mean of urinary albumin creatinine ratio in Normoalbuminuria was 
13.64+/-7.66.It is lower than the mean of  Microalbuminuria 127.98+/-81.23. 
Similarly mean value of serum albumin in Normoalbuminuria, 3.90+/-0.56g/dL 
was lower compared to Microalbuminuria mean value of 3.62+/-0.50g/dL. 
 
 Microalbuminuria is asssociated with the state of subclinical 
inflammation and endothelial dysfunction(152,153) . It activates the Macrophages  
and  upregulates the synthesis of  IL-1,IL-6, & TNF and increases the production 
of  hs-CRP. It explains the association between Microalbuminuria and 
cardiovascular disease. 
 
In this study, Correlation was done to measure the linear relation ship between 
 e GFR & Uricacid,   
 Uric acid &hs-cRP. 
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URIC ACID &eGFR: 
 Strong negative Correlation was observed . It indicates that when the 
concentration of  Uric acid increases, eGFR decreases  which implies impaired 
renal function. 
 
 Uric acid causes thickening &hypercellularity of Glomerulus & induces 
epithelial mesenchymal transition of renal tubular cell resulting in increased 
medial thickness  and decreased luminal diameter  & it contributes to the 
decrease in Glomerular filtration rate(154,155). 
 
URICACID&hs-CRP:   
 Strong  Positive correlation was observed. It  indicates when the 
concentration  of uricacid increases, hs-CRP  also increases. 
 
 Uricacid acts as a  prooxidant. It increases the production of Monocyte 
chemoattractant protein -1 through cyclooxygenase-2 & MAP kinase pathway 
resulting  in  increased production of  hs-CRP(156-159). 
 
 hs-CRP directly binds  oxidised LDL and present  with in lipid laden 
plaques.It is a proinflammatory trigger in  plaque deposition, leading to 
macrophage infiltration in atherosclerotic lesions. It increases the expression of 
tissue factor which can lead to thrombosis  during inflammatory states. 
 
 Mean TGL of microalbuminuria was 117.13+/-61.79mg/dL which is 
higher than the mean TGL of  Normoalbuminuria 97.49+/-44.28 mg/dL.The 
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results of our study matches  EURODIAB IDDM  Complication study,  where 
Microalbuminuria was associated with increased plasma triglyceride level.(160) 
 
 Some Quantitative lipid modifications  may occur in Type 1 Diabetic 
patients with Microalbuminuria..Hypertriglyceridemia occurs mainly due to 
decreased lipoprotein lipase activity secondary to insulin deficiency. 
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CONCLUSION 
 
 The present study was done with an aim to find out the correlation of 
serum uric acid with GFR in normoalbuminuric & microalbuminuric Type 1 
Diabetic patients and  its correlation with  hs-CRP for predicting cardiovascular 
risk. 
 
From this study, we  conclude  that, 
 Serum uric acid is an independent determinant of  GFR in Type 1 
Diabetic patients. 
 There is a significant  negative correlation of uric acid with  GFR in Type 
1 Diabetic patients. 
 There is a significant  positive correlation between hs-CRP and uric acid 
levels. 
 Serum uric acid &hs-CRP can be  used to assess the renal & 
cardiovascular risk in Type 1 Diabetic patients particularly in patients 
with low GFR. 
 It is also cost effective to measure serum Uric acid  & hs-CRP  in  Type 1 
Diabetes even in Normoalbuminuria, to assess the  renal & cardiovascular 
risk  earlier particularly in Indian clinical settings, where the early 
detection rate of Diabetes was lower and complications were higher. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limitations of the 
study 
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LIMITATIONS OF THE STUDY 
 
 Even though there is  a significant  association between  elevated uric acid 
concentration and decline in renal function, randomized controlled trials are  
essential to evaluate  the role of uric acid lowering drugs in the  prevention of  
further impairment  of renal function .  
 
 Prospective cohort studies are needed to confirm  elevated hs-CRP levels in 
type 1 Diabetic patients are associated with Cardiovascular disease. 
 Being a tertiary care hospital based study , a large community based  study in 
Indian population is needed to verify the findings in general population 
 
 Our study was carried out only in Type 1 Diabetic patients, and whether the 
result can be extrapolated to patients with Type 2 Diabetes is uncertain. 
 
 
  
  
 
Future prospects  
of the study 
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FUTURE PROSPECTS OF THE STUDY 
 Uric acid may be in future used as a marker of 
 Oxidant damage in ischemic liver injury . 
 Ischemic reperfusion injury 
 
 To our knowledge this is the first study to be conducted in India evaluating  
hs CRP and Uric Acid in type 1 diabetes. In India renal replacement therapy 
is a great burden to the health system. Larger studies if confirm our results 
may help in identifying and risk stratifying patients who might end up in End 
stage renal disease later. Earlier institution of renoprotective measures would 
reduce the overall burden on the system.  
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Annexures 
 
 
 INFORMATION SHEET 
 
 Your blood sample has been accepted. 
 We are conducting a study on type1 diabetic  patients  among patients 
attending Government General Hospital, Chennai and for that your 
blood sample may be valuable to us. 
 The purpose of this study is to find out the role of  uricacid&hs-CRP    
as a renal& cardiovascular risk marker in  type 1 diabetic patients with 
low GFR. with the help of certain special tests. 
 We are selecting certain cases and if your blood sample is found 
eligible, we may be using your blood sample to perform extra tests and 
special studies which in any way do not affect your final report or 
management. 
 The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from 
the research, no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will 
not result in any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which 
may aid in the management or treatment. 
 
Signature of investigator                                               Signature of participant 
Date: 
 
 
 PATIENT CONSENT FORM 
Title of the study :" ROLE OF URICACID AND hs-CRP  AS  RENAL AND 
CARDIOVASCULAR RISK MARKERS  IN  TYPE  1 DIABETIC PATIENTS 
WITH LOW GFR" . 
 
Name :        Date  : 
Age :        OP No  :
  
Sex :        Project Patient No
 : 
 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I  
hereby give my consent to be included as a participant in “ROLE OF URICACID 
AND hs-CRP AS RENAL AND CARDIOVASCULAR RISK MARKERS  IN   
TYPE  1 DIABETIC PATIENTS WITH LOW GFR.”. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator.  
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past ________ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately if 
I suffer unusual symptoms. 
8. I have not participated in any research study within the past ________ month(s). 
9. I am aware of the fact that I can opt out of the study at any time without having to 
give my reason and this will not affect my future treatment in this hospital. 
10. I am also aware that the investigator may terminate my participation in the study 
at any time, for any reason, without any consent. 
11. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly presented. 
12. I have understand that my identity will be kept confidential if my data are publicly 
presented. 
13. I have had my questions answered to my satisfaction. 
14. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
 
For  participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant  in competent/For age 10-17 yrs-Name& signature of the parent/guardian.) 
 
Name _________________________ Signature______________Date___________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name _________________________ Signature______________ Date___________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature______________ Date___________ 
  
  
 
  
 

  
  
Investigations: 
Serum fasting glucose : 
Lipid Profile    :  TGL  HDL  LDL 
Serum Creatinine   : 
Serum Urea    : 
Serum Protein   : 
Serum Albumin   : 
eGFR (CKD-EPI)   : 
Spot Urine Albumin  : 
Spot Urine Creatinine  : 
Albumin Creatinine Ratio  : 
Serum hs-CRP   : 
Serum HbA1C   : 
Serum Uric Acid   : 
 
 
